<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Psychol Med</journal-id><journal-id journal-id-type="iso-abbrev">Psychol Med</journal-id><journal-id journal-id-type="pmc-domain-id">937</journal-id><journal-id journal-id-type="pmc-domain">cambridgeopen</journal-id><journal-id journal-id-type="publisher-id">PSM</journal-id><journal-title-group><journal-title>Psychological Medicine</journal-title></journal-title-group><issn pub-type="ppub">0033-2917</issn><issn pub-type="epub">1469-8978</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Cambridge Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12080641</article-id><article-id pub-id-type="pmcid-ver">PMC12080641.1</article-id><article-id pub-id-type="pmcaid">12080641</article-id><article-id pub-id-type="pmcaiid">12080641</article-id><article-id pub-id-type="pmid">40071563</article-id><article-id pub-id-type="doi">10.1017/S0033291725000388</article-id><article-id pub-id-type="pii">S0033291725000388</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Sociodemographic, clinical, and genetic factors associated with self-reported antidepressant response outcomes in the UK Biobank</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4334-6883</contrib-id><name name-style="western"><surname>Kamp</surname><given-names initials="M">Michelle</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3219-8942</contrib-id><name name-style="western"><surname>Lo</surname><given-names initials="CWH">Chris Wai Hang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6320-3222</contrib-id><name name-style="western"><surname>Kokkinidis</surname><given-names initials="G">Grigorios</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chauhan</surname><given-names initials="M">Mimansa</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5069-3197</contrib-id><name name-style="western"><surname>Gillett</surname><given-names initials="AC">Alexandra C.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><collab collab-type="author">AMBER Research Team</collab></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0198-4588</contrib-id><name name-style="western"><surname>McIntosh</surname><given-names initials="AM">Andrew M.</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5680-3281</contrib-id><name name-style="western"><surname>Pain</surname><given-names initials="O">Oliver</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8249-8476</contrib-id><name name-style="western"><surname>Lewis</surname><given-names initials="CM">Cathryn M.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &amp; Neuroscience, <institution>King&#8217;s College London</institution>, <city>London</city>, <country>UK</country>
</aff><aff id="aff2">
<label>2</label>NIHR Maudsley Biomedical Research Centre, <institution>South London and Maudsley NHS Trust</institution>, <city>London</city>, <country>UK</country>
</aff><aff id="aff3">
<label>3</label>Division of Psychiatry, <institution>University of Edinburgh</institution>, <city>Edinburgh</city>, <country>UK</country>
</aff><aff id="aff4">
<label>4</label>Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, <institution>King&#8217;s College London</institution>, <city>London</city>, <country>UK</country>
</aff><aff id="aff5">
<label>5</label>Department of Medical and Molecular Genetics, Faculty of Life Sciences and Medicine, <institution>King&#8217;s College London</institution>, <city>London</city>, <country>UK</country>
</aff><author-notes><corresp id="cor1"><bold>Corresponding author:</bold> Michelle Kamp; Email: <email>michelle.kamp@kcl.ac.uk</email></corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2025"><year>2025</year></pub-date><pub-date pub-type="epub"><day>12</day><month>3</month><year>2025</year></pub-date><volume>55</volume><issue-id pub-id-type="pmc-issue-id">488656</issue-id><elocation-id>e80</elocation-id><history><date date-type="received"><day>09</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>13</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>16</day><month>05</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-16 10:25:47.777"><day>16</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0</uri>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="S0033291725000388a.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="S0033291725000388a.pdf"/><abstract><sec id="sec1"><title>Background</title><p>In major depressive disorder (MDD), only ~35% achieve remission after first-line antidepressant therapy. Using UK Biobank data, we identify sociodemographic, clinical, and genetic predictors of antidepressant response through self-reported outcomes, aiming to inform personalized treatment strategies.</p></sec><sec id="sec2"><title>Methods</title><p>In UK Biobank Mental Health Questionnaire 2, participants with MDD reported whether specific antidepressants helped them. We tested whether retrospective lifetime response to four selective serotonin reuptake inhibitors (SSRIs) (<italic toggle="yes">N</italic> = 19,516) &#8211; citalopram (<italic toggle="yes">N</italic> = 8335), fluoxetine (<italic toggle="yes">N</italic> = 8476), paroxetine (<italic toggle="yes">N</italic> = 2297) and sertraline (<italic toggle="yes">N</italic> = 5883) &#8211; was associated with sociodemographic (e.g. age, gender) and clinical factors (e.g. episode duration). Genetic analyses evaluated the association between CYP2C19 variation and self-reported response, while polygenic score (PGS) analysis assessed whether genetic predisposition to psychiatric disorders and antidepressant response predicted self-reported SSRI outcomes.</p></sec><sec id="sec3"><title>Results</title><p>71%&#8211;77% of participants reported positive responses to SSRIs. Non-response was significantly associated with alcohol and illicit drug use (OR = 1.59, <italic toggle="yes">p</italic> = 2.23 &#215; 10<sup>&#8722;20</sup>), male gender (OR = 1.25, <italic toggle="yes">p</italic> = 8.29 &#215; 10<sup>&#8722;08</sup>), and lower-income (OR = 1.35, <italic toggle="yes">p</italic> = 4.22 &#215; 10<sup>&#8722;07</sup>). The worst episode lasting over 2 years (OR = 1.93, <italic toggle="yes">p</italic> = 3.87 &#215; 10<sup>&#8722;16</sup>) and no mood improvement from positive events (OR = 1.35, <italic toggle="yes">p</italic> = 2.37 &#215; 10<sup>&#8722;07</sup>) were also associated with non-response. CYP2C19 poor metabolizers had nominally higher non-response rates (OR = 1.31, <italic toggle="yes">p</italic> = 1.77 &#215; 10<sup>&#8722;02</sup>). Higher PGS for depression (OR = 1.08, <italic toggle="yes">p</italic> = 3.37 &#215; 10<sup>&#8722;05</sup>) predicted negative SSRI outcomes after multiple testing corrections.</p></sec><sec id="sec4"><title>Conclusions</title><p>Self-reported antidepressant response in the UK Biobank is influenced by sociodemographic, clinical, and genetic factors, mirroring clinical response measures. While positive outcomes are more frequent than remission reported in clinical trials, these self-reports replicate known treatment associations, suggesting they capture meaningful aspects of antidepressant effectiveness from the patient&#8217;s perspective.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>antidepressant response</kwd><kwd>CYP2C19 metabolizer status</kwd><kwd>major depressive disorder (MDD)</kwd><kwd>polygenic scores</kwd><kwd>selective serotonin reuptake inhibitors (SSRIs)</kwd></kwd-group><counts><fig-count count="4"/><table-count count="1"/><ref-count count="69"/><page-count count="13"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec5"><title>Introduction</title><p>Major depressive disorder (MDD) is a prevalent and debilitating condition characterized by persistent low mood, loss of interest, cognitive impairment, and physical symptoms such as disrupted sleep or appetite (Otte et al., <xref rid="r39" ref-type="bibr">2016</xref>). Affecting approximately one in six adults globally, MDD incidence continues to rise annually (Abdoli et al., <xref rid="r1" ref-type="bibr">2022</xref>; GBD 2019). In 2018, the World Health Organization (WHO) ranked MDD third in global disease burden and predicted it will be the leading cause by 2030 (Cui et al., <xref rid="r9" ref-type="bibr">2024</xref>).</p><p>Antidepressants, specifically selective serotonin reuptake inhibitors (SSRIs), are first-line pharmacological treatments for MDD (Bauer, Severus, M&#246;ller, &amp; Young, <xref rid="r3" ref-type="bibr">2017</xref>; Cleare et al., <xref rid="r8" ref-type="bibr">2015</xref>; NICE, <xref rid="r37" ref-type="bibr">2009</xref>). In England&#8217;s National Health Service (NHS), antidepressant prescriptions nearly doubled from 36 million in 2008 to 70.9 million in 2018 (Iacobucci, <xref rid="r23" ref-type="bibr">2019</xref>). SSRIs have similar or greater efficacy than other antidepressants and are preferred clinically for their fewer side effects (Cipriani et al., <xref rid="r7" ref-type="bibr">2018</xref>; Karrouri, Hammani, Benjelloun, &amp; Otheman, <xref rid="r28" ref-type="bibr">2021</xref>). However, antidepressant efficacy varies with only ~35% of patients achieving remission after initial treatment (Rush et al., <xref rid="r49" ref-type="bibr">2006</xref>), and approximately 40% developing treatment-resistant depression, defined as the lack of response to two or more antidepressants in the same depressive episode (Rush et al., <xref rid="r48" ref-type="bibr">2011</xref>; Souery et al., <xref rid="r53" ref-type="bibr">2011</xref>).</p><p>Variability in treatment response may be due to disorder heterogeneity (Cui et al., <xref rid="r9" ref-type="bibr">2024</xref>; Fried &amp; Nesse, <xref rid="r15" ref-type="bibr">2015</xref>), genetics (Pain et al., <xref rid="r41" ref-type="bibr">2022</xref>; Tansey et al., <xref rid="r58" ref-type="bibr">2013</xref>), and sociodemographic or clinical factors (Perna et al., <xref rid="r43" ref-type="bibr">2020</xref>). While studies assessing the impact of age and sex on antidepressant response show inconsistent results (Kessler et al., <xref rid="r29" ref-type="bibr">2017</xref>; Khan et al., <xref rid="r30" ref-type="bibr">2005</xref>; Perna et al., <xref rid="r43" ref-type="bibr">2020</xref>; Saveanu et al., <xref rid="r51" ref-type="bibr">2015</xref>; Trivedi et al., <xref rid="r59" ref-type="bibr">2006</xref>); socioeconomic factors such as low income and unemployment have been associated with poor response to the antidepressant citalopram (Trivedi et al., <xref rid="r59" ref-type="bibr">2006</xref>). Genome-wide association studies (GWASs) have yet to find robust genetic predictors of antidepressant response, likely due to small sample sizes, study design, and drug and outcome heterogeneity (Ising et al., <xref rid="r25" ref-type="bibr">2009</xref>; Ji et al., <xref rid="r27" ref-type="bibr">2013</xref>; Uher et al., <xref rid="r60" ref-type="bibr">2009</xref>). Nevertheless, SNP-based heritability estimates by the Psychiatric Genomics Consortium suggest that 13% to 40% of the variance in antidepressant response is attributable to common genetic variation (Pain et al., <xref rid="r41" ref-type="bibr">2022</xref>).</p><p>Pharmacogenetic studies have identified variations in the cytochrome P450 (CYP) enzyme superfamily that affects drug response via pharmacokinetic mechanisms. Polymorphisms in <italic toggle="yes">CYP</italic> genes, including <italic toggle="yes">CYP2C19</italic>, impact enzyme activity and may explain individual differences in treatment response (Li et al., <xref rid="r32" ref-type="bibr">2024</xref>; Wong et al., <xref rid="r65" ref-type="bibr">2023</xref>). However, CYP2C19 and other candidate genes account for only a small fraction of variability in drug response. Polygenic scores (PGS) offer an alternative by quantifying an individual&#8217;s genetic predisposition to a trait or disease, aggregating the effects of multiple SNPs identified through GWAS. By capturing the polygenic nature of treatment response, where many loci contribute small effects, PGS may be valuable for predicting response. Although PGS for bipolar disorder and MDD, based on relatively small sample sizes, have shown inconsistent associations with treatment outcomes (Fanelli et al., <xref rid="r14" ref-type="bibr">2021</xref>; Garc&#237;a-Gonz&#225;lez et al., <xref rid="r16" ref-type="bibr">2017</xref>), positive antidepressant response has been associated with low genetic liability for schizophrenia (Pain et al., <xref rid="r41" ref-type="bibr">2022</xref>).</p><p>The trial-and-error approach to finding the right antidepressant delays recovery, increases side effects, reduces adherence, and highlights the need to identify individual moderators of treatment response to support personalized treatments (Perna et al., <xref rid="r43" ref-type="bibr">2020</xref>). Most studies identifying factors associated with antidepressant response come from clinical trials, which often have limited generalizability due to restrictive inclusion criteria and controlled settings. However, comprehensive datasets, including retrospective self-reports on antidepressant response, are becoming available (Koch et al., <xref rid="r31" ref-type="bibr">2024</xref>). Little is known about predictors associated with an SSRI-user reporting that an antidepressant &#8216;helped&#8217; them. This study uses retrospective self-report data from approximately 20,000 UK Biobank participants to assess sociodemographic, clinical, and genetic predictors of this patient-focused measure of SSRI response and compare them with those identified in prospective clinical studies.</p></sec><sec sec-type="methods" id="sec6"><title>Method</title><sec sec-type="other" id="sec7"><title>Participants</title><p>The UK Biobank (UKB) is a large-scale research resource investigating the impact of genetic, environmental, and lifestyle factors on health outcomes in middle-aged and older adults. Individuals aged 40&#8211;69 registered with the UK National Health Service were invited to participate, and 500,000 individuals were recruited in 22 assessment centers across the UK between 2006 and 2010 (Allen, Sudlow, Peakman, &amp; Collins, <xref rid="r2" ref-type="bibr">2014</xref>). Baseline data included sociodemographic characteristics, medical histories, and health and lifestyle factors. Two online mental health questionnaires have been issued. The second questionnaire (MHQ2; Category 1502), which was initiated in 2022 and completed by 172,912 participants, included information on treatment (MHQ2 resources are available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://osf.io/c65t7/">https://osf.io/c65t7/</uri>). Participants who endorsed at least one of two cardinal lifetime MDD symptom screening questions (UKB fields 29011 and 29012, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S1</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Table&#160;S1</uri>) completed the medication and antidepressant response sections (<italic toggle="yes">N</italic> = 79,888). After excluding participants with prior or probable schizophrenia, bipolar, or mania diagnoses (<italic toggle="yes">N</italic> = 1527, from UKB fields 29000 and 20126) and those missing genetic information (1835 individuals), 76,526 individuals with unipolar MDD were available for this analysis.</p><p>Prescription medication users (Yes/No) (<italic toggle="yes">N</italic> = 35,088) were identified as those who reported trying prescribed medication for low mood or anhedonia (UKB field 29038, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S1</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Table&#160;S1</uri>). Antidepressant users were prescription medication users who reported trying specific antidepressants for at least 2 weeks (UKB field 29039), with four SSRIs listed: citalopram, fluoxetine, paroxetine, or sertraline (<italic toggle="yes">N</italic> = 20,613) (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S1</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Figure&#160;S1</uri>). SSRIs were limited to these four drugs as they were the options listed in MHQ2, aligning with prescription records showing they account for over 90% of prescribed antidepressants in the UK: citalopram (36%), fluoxetine (33%), paroxetine (12%), and sertraline (15%) (Lo et al., <xref rid="r33" ref-type="bibr">2024</xref>).</p></sec><sec sec-type="other" id="sec8"><title>Ethics and consent</title><p>The UK Biobank has research ethics approval from the North West Multi-center Research Ethics Committee (MREC; approval number 11/NW/0382) covering the UK. Participation is voluntary, and participants can withdraw at any time. Informed written consent was obtained at baseline. The current study was performed under UK Biobank application 82087. All relevant ethical guidelines have been followed during the analysis.</p></sec><sec sec-type="other" id="sec9"><title>Measures</title><sec sec-type="other" id="sec10"><title>Self-reported antidepressant response outcomes</title><p>The antidepressant response was restricted to 19,516 SSRI users who reported &#8220;Yes, even a little (Y)&#8221; or &#8220;No (N)&#8221; to whether at least one of the SSRIs &#8211; citalopram, fluoxetine, paroxetine, sertraline &#8211; had helped them &#8220;feel better&#8221; (UKB field 29040, 29041, 29042, and 29043). Those who responded &#8220;Do not know&#8221; and &#8220;Prefer not to answer&#8221; were excluded.</p><sec sec-type="other" id="sec11"><title>SSRI antidepressant response</title><p>The primary outcome for this study was SSRI response, coded as Y/N. For participants using multiple SSRIs, consistent responses across antidepressants (i.e. all &#8220;Y,&#8221; or all &#8220;N&#8221;) were categorized &#8220;Y&#8221; or &#8220;N&#8221; accordingly. For any participant reporting &#8220;N&#8221; for any antidepressant their composite-SSRI response was &#8220;N.&#8221; In all analyses, the reference category for SSRI response was a positive response.</p><p>A sensitivity analysis using a binary SSRI-conservative outcome was conducted for participants using multiple SSRIs, assigning a missing value where only one &#8220;N&#8221; was reported (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S1</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Table&#160;S2</uri>). In addition, four binary drug-specific response outcomes were defined as part of a sensitivity analysis for sociodemographic and clinical variables. A positive response was defined as &#8220;Y&#8221; to where users had responded &#8220;Yes, even a little,&#8221; to whether the specific SSRI (citalopram, fluoxetine, paroxetine, or sertraline) helped them &#8220;feel better.&#8221; Each drug-specific response was analyzed independently of other self-reported antidepressant exposures. For genetic variables, namely CYP2C19 metabolizer status and psychiatric disorder PGS (described in <italic toggle="yes">Genetic factors</italic>), drug-specific effects are important and tested as a primary outcome.</p></sec></sec><sec sec-type="other" id="sec12"><title>Sociodemographic factors</title><p>Sociodemographic variables collected at baseline UKB assessment were analyzed, including age, sex, ethnicity, educational attainment, household income, and neighborhood deprivation. Age at recruitment was recorded in years. Gender was self-reported as biological sex (female/male). Ethnic background was self-reported as &#8220;Asian or Asian British,&#8221; &#8220;Black or Black British,&#8221; &#8220;Mixed background,&#8221; &#8220;White&#8221; and &#8220;Other ethnic group&#8221;; for analysis, categories were grouped as &#8220;Asian,&#8221; &#8220;Black,&#8221; &#8220;Mixed,&#8221; and &#8220;White,&#8221; with White as the reference.</p><p>Educational attainment was classified into five categories based on highest education level achieved (Rayner et al., <xref rid="r46" ref-type="bibr">2021</xref>): &#8216;Secondary&#8217; for completion of compulsory secondary education (GCSE level, 11 years of education); &#8216;Further&#8217; for completion of further education (A-levels, 13 years); &#8216;Vocational&#8217; for a range of vocational and professional qualifications (NVQs, BTECs, Apprenticeships, &#8805;12 years); and &#8216;University&#8217; for university-level education (Degree, &#8805;16 years); &#8216;None&#8217; for none of those listed as the modal category, University was set as the reference. Annual household income was divided into five categories: Less than &#163;18,000, &#163;18,000&#8211;&#163;31,000, &#163;31,000&#8211;&#163;52,000, &#163;52,000&#8211;&#163;100,000, and Greater than &#163;100,000, with the median category (&#163;30,000&#8211;&#163;52,000) serving as the reference.</p><p>Neighborhood deprivation was measured using the Townsend Deprivation Index (TDI), which combines four census variables (unemployment, car ownership, homeownership, household overcrowding), standardized and summed to a total score. Areas with TDI &gt; 0 are more deprived, while TDI &lt; 0 indicates more affluent areas. The variable &#8220;illicit drug and alcohol use&#8221; was derived from participants&#8217; reports of using drugs and alcohol to manage their two cardinal MDD symptoms as these coping mechanisms have been linked to treatment-seeking behavior for MDD (Rayner et al., <xref rid="r46" ref-type="bibr">2021</xref>).</p></sec><sec sec-type="other" id="sec13"><title>Clinical factors</title><p>MDD symptoms during a participant&#8217;s worst episode of MDD are available for UKB participants who answered relevant questions derived from the Composite International Diagnostic Interview (CIDI) conducted through the MHQ2, data category 1502 (World Health Organization, <xref rid="r66" ref-type="bibr">1993</xref>). The questions identify key depression symptoms, including persistent sadness, loss of interest or pleasure, changes in weight or sleep, fatigue, guilt, worthlessness, concentration difficulties, and suicidal ideation (World Health Organization, <xref rid="r66" ref-type="bibr">1993</xref>).</p><p>The MHQ2 also assessed clinical characteristics of MDD through self-report, including the lifetime number of depressive periods, age at first and last episode, and whether episodes were related to childbirth or trauma. Family history of severe depression was determined if the participant reported their father, mother or sibling experienced severe depression (UKB field 20107, 20110, 20111); as the modal category, &#8220;No&#8221; was the reference category. The full list of clinical variables, their data fields, and reference categories used in this analysis are in <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S1</uri> (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Table&#160;S3</uri>).</p></sec><sec sec-type="other" id="sec14"><title>Genetic factors</title><p>Genome-wide genotyping is available for all UKB participants. Samples underwent standard quality control (QC) and imputation. Further description of UKB samples, as well as details on genotyping QC and imputation, is available in <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S1</uri>.</p><sec sec-type="other" id="sec15"><title>CYP2C19 metabolizer status</title><p>CYP2C19 is a key enzyme in SSRI metabolism, with genetic variation in the CYP2C19 gene associated with differential metabolic activity and, consequently, differential SSRI exposure. Metabolic capacity is determined by specific allelic variants, with the patient classified into one of five metabolizer groups based on genotypes and corresponding enzymatic function - poor (no functional enzyme), intermediate (reduced enzyme activity), normal (normal enzyme activity), rapid, and ultra-rapid (increased enzyme activity). CYP2C19 genotypes and metabolizer status were obtained from UKB return 3388 as described by McInnes et al. (McInnes et al., <xref rid="r34" ref-type="bibr">2021</xref>). In brief, pharmacogenetic star alleles and metabolizer phenotypes were identified using the Python program PGxPOP, which determines and reports pharmacogenetic star alleles (popular nomenclature that corresponds to functional haplotype patterns that influence drug metabolism) and haplotypes from phased multisample VCFs using PharmCAT allele definition files (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/PharmGKB/PharmCAT)">https://github.com/PharmGKB/PharmCAT)</uri> (Sangkuhl et al., <xref rid="r50" ref-type="bibr">2020</xref>). PGxPOP applies guidelines from the Dutch Pharmacogenetics Working Group (DPWG) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) to correlate haplotypes with predicted metabolic phenotypes. Participants were categorized into five metabolic phenotypes &#8211; poor (PM), intermediate (IM), normal (NM), rapid (RM), and ultrarapid (UM) &#8211; based on predicted CYP2C19 activity. Individuals with &#8220;indeterminate&#8221; or &#8220;not available&#8221; phenotypes were excluded due to unknown, uncertain, or unaligned star allele functions, preventing phenotype assignment.</p></sec><sec sec-type="other" id="sec16"><title>Polygenic scores</title><p>Polygenic scores were calculated for five psychiatric conditions and two antidepressant response outcomes using GWAS summary statistics from the Psychiatric Genomics Consortium (Demontis et al., <xref rid="r12" ref-type="bibr">2019</xref>; Grove et al., <xref rid="r19" ref-type="bibr">2019</xref>; Pain et al., <xref rid="r41" ref-type="bibr">2022</xref>; Pardi&#241;as et al., <xref rid="r42" ref-type="bibr">2018</xref>; Stahl et al., <xref rid="r54" ref-type="bibr">2019</xref>; Wray et al., <xref rid="r67" ref-type="bibr">2018</xref>) (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S1</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Table&#160;S4</uri>). The psychiatric conditions included depression (DEPR), autism (AUTI), Attention-Deficit/Hyperactivity Disorder (ADHD), bipolar disorder (BIPO), and schizophrenia (SCHI). The two antidepressant response outcomes were percentage improvement (ADperc), and non-remission (ADnon-rem) (Pain et al., <xref rid="r41" ref-type="bibr">2022</xref>). ADperc was calculated as 100*(baseline depression score &#8722; final depression score)/baseline depression score, with higher ADperc indicating better treatment response. Remission is a binary measure attained when a patient&#8217;s depression symptom score decreases to a pre-specified threshold for the relevant rating scale. Patients who did not reach these thresholds were classified as non-remitting (Pain et al., <xref rid="r41" ref-type="bibr">2022</xref>).</p><p>PGS was calculated using the MegaPRS method within the GenoPred Pipeline (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://opain.github.io/GenoPred/">https://opain.github.io/GenoPred/</uri>) (Pain, Al-Chalabi, &amp; Lewis, <xref rid="r40" ref-type="bibr">2024</xref>). The MegaPRS model selected by its pseudo-summary approach was used in downstream analyses. The pseudo-summary approach estimates the best tuning parameters based solely on the GWAS summary statistics, avoiding the need for an external validation sample. MegaPRS was used due to its superior prediction performance for psychiatric disorders (Ni et al., <xref rid="r36" ref-type="bibr">2021</xref>). Covariates included the first six principal components (to adjust for population stratification), age, sex, and genotyping batch. The assessment center was excluded as a covariate as association testing showed no significant association with self-reported response outcomes (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S1</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Table&#160;S5</uri>).</p></sec></sec></sec><sec sec-type="other" id="sec17"><title>Statistical analyses</title><p>The primary outcome analyzed was self-reported binary SSRI response (Y/N). Separate association analyses assessed associations between sociodemographic, clinical, and genetic predictors with SSRI response using univariable and multivariable logistic regression models and the odds ratio (OR) reported. The reference level was a positive response; hence, all ORs describe the odds of SSRI non-response compared to a positive response. Clinical variables reaching nominal significance were taken forward into multivariable models. For all analyses, variance inflation factors assessed multicollinearity in multivariable models (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S1</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Tables&#160;S9&#160;and&#160;S10</uri>) and covariates included age and sex. Sensitivity analyses for drug-specific responses are presented in the <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Data&#160;S1</uri>. Clinical and genomic analyses were limited to White Western European ancestry participants due to insufficient sample sizes in other ancestries.</p><p>To address drug-specific genetic effects, genetic analyses included overall SSRI responses and drug-specific responses (Citalopram, Fluoxetine, Paroxetine, and Sertraline). All analyses were conducted using R (version 4.2.2). Logistic regressions were performed using the <italic toggle="yes">glm</italic> function (R Core Team, <xref rid="r44" ref-type="bibr">2021</xref>). Associations between PGS and self-reported antidepressant response were reported as the OR for the standardized PGS. Each multivariable model underwent Bonferroni correction; the correction accounted for the total number of predictors (and their levels) assessed in the study (i.e. sociodemographic, clinical, and genetic factors) to allow for comparability across predictor groups (<italic toggle="yes">p</italic> = 0.05/55 = 0.0009). Sensitivity and genetic analyses included an additional correction for multiple testing across six outcomes (<italic toggle="yes">p</italic> = 0.05/330 = 0.0002). Figures display the SSRI response phenotype only. Genetic association plots show SSRI response as well as drug-specific associations.</p></sec></sec><sec sec-type="results" id="sec18"><title>Results</title><sec sec-type="other" id="sec19"><title>Characteristics</title><p>A total of 76,526 individuals with unipolar MDD were included in this analysis. Of these, 45.9% (<italic toggle="yes">N</italic> = 35,088) used prescription medications to alleviate symptoms, and 36.6% (<italic toggle="yes">N</italic> = 27,977) tried antidepressants. About one-quarter (26.9%, <italic toggle="yes">N</italic> = 20,613) used at least one SSRI. <xref rid="fig1" ref-type="fig">Figure 1</xref> presents the total number of SSRI and specific drug counts among SSRI users. Across groups, approximately 7% responded with &#8220;Do not know&#8221; and &lt;1% with &#8220;Prefer not to answer&#8221; (<xref rid="fig1" ref-type="fig">Figure 1</xref>); these individuals were excluded from further analysis. Final sample sizes were citalopram (<italic toggle="yes">N</italic> = 8335), fluoxetine (<italic toggle="yes">N</italic> = 8476), paroxetine (<italic toggle="yes">N</italic> = 2297), and sertraline (<italic toggle="yes">N</italic> = 5883) (<xref rid="fig1" ref-type="fig">Figure 1</xref>). As participants could use multiple SSRIs, the total count for SSRI in <xref rid="fig1" ref-type="fig">Figure 1</xref> exceeds the number of unique participants. To address this, a decision framework (Methods: 2.33) was applied, resulting in 19,516 unique individuals for the SSRI response phenotype and 18,170 individuals for the conservative-SSRI group. Over three-quarters (77.8%) of SSRI individuals tried a single SSRI for at least 2 weeks, with citalopram and fluoxetine being the most common (~35% each), followed by sertraline (21%) and paroxetine (8%). Approximately 5% tried three or more of these SSRIs (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S1</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Figure&#160;S3</uri>).<fig position="float" id="fig1" orientation="portrait"><label>Figure 1.</label><caption><p>Distribution of the total number of SSRI responses in a subset of UKB participants reporting at least one of the two cardinal symptoms of MDD. SSRI count does not match the number of participants taking SSRIs as some participants reported taking more than one antidepressant. Participants reported &#8216;Yes&#8217; or &#8216;No&#8217; that the SSRI drug helped them.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0033291725000388_fig1.jpg"/></fig></p><p>For participants who responded positively to at least one cardinal MDD question, we compared those who had (<italic toggle="yes">N</italic> = 19,516) and had not (<italic toggle="yes">N</italic> = 57,010) tried SSRIs. SSRI users were younger (55.0 &#177; 7.5 years vs. 52.5 &#177; 7.3 years, <italic toggle="yes">p</italic> &lt; 1.00 &#215; 10<italic toggle="yes"><sup>&#8722;300</sup></italic>; <xref rid="tab1" ref-type="table">Table 1</xref>), more likely to be female (63.7 vs. 73.6%, <italic toggle="yes">p</italic> = 2.08 &#215; 10<sup>&#8722;142</sup>) and of white ethnicity (97.9 vs. 98.5%, <italic toggle="yes">p</italic> = 6.18 &#215; 10<sup>&#8722;10</sup>). SSRI users also had lower income (annual household income &lt;&#163;18,000: 13.9 vs. 16.4%, <italic toggle="yes">p</italic> = 1.50 &#215; 10<sup>&#8722;23</sup>), came from less deprived neighborhoods (&#8722;1.6 vs. &#8722;1.4, <italic toggle="yes">p</italic> = 7.98 &#215; 10<sup>&#8722;11</sup>) and were less likely to have a university degree (46.3 vs. 43.8%, <italic toggle="yes">p</italic> = 5.17 &#215; 10<sup>&#8722;18</sup>).<table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1.</label><caption><p>Participant characteristics among those who have and have not tried selective serotonin reuptake inhibitors (SSRI) in a subsample of the UKB participants reporting at least one of the two cardinal symptoms for MDD</p></caption><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1" valign="bottom"/><th align="center" valign="bottom" rowspan="1" colspan="1">SSRI not tried</th><th align="center" valign="bottom" rowspan="1" colspan="1">SSRI tried</th><th rowspan="1" colspan="1" valign="bottom"/></tr><tr><th rowspan="1" colspan="1" valign="bottom"/><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#160;=&#160;57,010</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#160;=&#160;19,516</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>-value<xref rid="tab1fn1" ref-type="table-fn"><sup>a</sup></xref>
</th></tr></thead><tbody><tr><td align="left" colspan="4" valign="bottom" rowspan="1"><bold>Age</bold>
</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#160;&#160;&#160;Mean (SD)</td><td align="center" valign="bottom" rowspan="1" colspan="1">55.0 (7.5)</td><td align="center" valign="bottom" rowspan="1" colspan="1">52.5 (7.3)</td><td align="left" rowspan="4" valign="middle" colspan="1">&lt;1.00&#160;&#215;&#160;10<sup>&#8722;300</sup></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#160;&#160;&#160;Median</td><td align="center" valign="bottom" rowspan="1" colspan="1">56</td><td align="center" valign="bottom" rowspan="1" colspan="1">52</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#160;&#160;&#160;Range (min, max)</td><td align="center" valign="bottom" rowspan="1" colspan="1">(40, 72)</td><td align="center" valign="bottom" rowspan="1" colspan="1">(40, 70)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#160;&#160;&#160;IQR</td><td align="center" valign="bottom" rowspan="1" colspan="1">(49, 61)</td><td align="center" valign="bottom" rowspan="1" colspan="1">(47, 58)</td></tr><tr><td align="left" colspan="4" valign="bottom" rowspan="1"><bold>Sex</bold>
</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#160;&#160;&#160;Female (%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">36,287 (64)</td><td align="center" valign="bottom" rowspan="1" colspan="1">14,368 (74)</td><td align="left" rowspan="2" valign="middle" colspan="1">2.08&#160;&#215;&#160;10<sup>&#8722;142</sup></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#160;&#160;&#160;Male (%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">20,723 (36)</td><td align="center" valign="bottom" rowspan="1" colspan="1">5148 (26)</td></tr><tr><td align="left" colspan="4" valign="bottom" rowspan="1"><bold>Ethnic background</bold>
</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#160;&#160;&#160;Asian (%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">431 (0.8)</td><td align="center" valign="bottom" rowspan="1" colspan="1">81 (0.4)</td><td align="left" rowspan="5" valign="middle" colspan="1">6.18&#160;&#215;&#160;10<sup>&#8722;10</sup></td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#160;&#160;&#160;Black (%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">375 (0.7)</td><td align="center" valign="bottom" rowspan="1" colspan="1">74 (0.4)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#160;&#160;&#160;Mixed (%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">361 (0.6)</td><td align="center" valign="bottom" rowspan="1" colspan="1">130 (0.7)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#160;&#160;&#160;White (%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">55,195 (98)</td><td align="center" valign="bottom" rowspan="1" colspan="1">19,081 (99)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#160;&#160;&#160;Missing</td><td align="center" valign="bottom" rowspan="1" colspan="1">648</td><td align="center" valign="bottom" rowspan="1" colspan="1">150</td></tr><tr><td align="left" colspan="4" valign="bottom" rowspan="1"><bold>Annual income</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#160;&#160;&#160;&lt;&#163;18,000 (%)</td><td align="center" valign="top" rowspan="1" colspan="1">7145 (14)</td><td align="center" valign="top" rowspan="1" colspan="1">2947 (16)</td><td align="left" rowspan="6" valign="middle" colspan="1">1.50&#160;&#215;&#160;10<sup>&#8722;23</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#160;&#160;&#160;&#163;18,000&#8211;&#163;31,000 (%)</td><td align="center" valign="top" rowspan="1" colspan="1">12,012 (23)</td><td align="center" valign="top" rowspan="1" colspan="1">15,038 (23)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#160;&#160;&#160;&#163;31,000&#8211;&#163;52,000 (%)</td><td align="center" valign="top" rowspan="1" colspan="1">15,038 (29)</td><td align="center" valign="top" rowspan="1" colspan="1">5399 (30)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#160;&#160;&#160;&#163;52,000&#8211;&#163;100,000 (%)</td><td align="center" valign="top" rowspan="1" colspan="1">13,509 (26)</td><td align="center" valign="top" rowspan="1" colspan="1">4407 (25)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#160;&#160;&#160;&gt;&#163;100,000 (%)</td><td align="center" valign="top" rowspan="1" colspan="1">3780 (7)</td><td align="center" valign="top" rowspan="1" colspan="1">1070 (6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#160;&#160;&#160;Missing</td><td align="center" valign="top" rowspan="1" colspan="1">5526</td><td align="center" valign="top" rowspan="1" colspan="1">1510</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1"><bold>Educational attainment</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#160;&#160;&#160;Secondary (GCSEs, 11&#160;years)</td><td align="center" valign="top" rowspan="1" colspan="1">7896 (14)</td><td align="center" valign="top" rowspan="1" colspan="1">2959 (15)</td><td align="left" rowspan="6" valign="middle" colspan="1">5.17&#160;&#215;&#160;10<sup>&#8722;18</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#160;&#160;&#160;Further (A-levels, 13&#160;years)</td><td align="center" valign="top" rowspan="1" colspan="1">7838 (14)</td><td align="center" valign="top" rowspan="1" colspan="1">2940 (15)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#160;&#160;&#160;Vocational (NVQs, BTECs, etc., &#8805;12&#160;years)</td><td align="center" valign="top" rowspan="1" colspan="1">11,142 (20)</td><td align="center" valign="top" rowspan="1" colspan="1">3995 (21)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#160;&#160;&#160;University (Degree, &#8805;16&#160;years)</td><td align="center" valign="top" rowspan="1" colspan="1">26,275 (46)</td><td align="center" valign="top" rowspan="1" colspan="1">8506 (44)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#160;&#160;&#160;None listed</td><td align="center" valign="top" rowspan="1" colspan="1">3562 (6)</td><td align="center" valign="top" rowspan="1" colspan="1">1020 (5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#160;&#160;&#160;Missing</td><td align="center" valign="top" rowspan="1" colspan="1">297</td><td align="center" valign="top" rowspan="1" colspan="1">96</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1"><bold>Townsend Deprivation Index (TDI)</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#160;&#160;&#160;Mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;1.6 (2.9)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;1.4 (3.0)</td><td align="left" rowspan="5" valign="middle" colspan="1">7.98&#160;&#215;&#160;10<sup>&#8722;11</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#160;&#160;&#160;Median</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;2.3</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;2.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#160;&#160;&#160;Range (min, max)</td><td align="center" valign="top" rowspan="1" colspan="1">(&#8722;6.3, 10.5)</td><td align="center" valign="top" rowspan="1" colspan="1">(&#8722;6.3, 11.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#160;&#160;&#160;IQR</td><td align="center" valign="top" rowspan="1" colspan="1">(&#8722;3.75, 0.05)</td><td align="center" valign="top" rowspan="1" colspan="1">(&#8722;3.67, 0.35)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#160;&#160;&#160;Missing</td><td align="center" valign="top" rowspan="1" colspan="1">74</td><td align="center" valign="top" rowspan="1" colspan="1">29</td></tr></tbody></table><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0033291725000388_tab1.jpg"/></alternatives><table-wrap-foot><fn id="tab1fn1" fn-type="other"><p><sup>a</sup> p-values was generated using Pearson&#8217;s chi-squared test for categorical variables and the Wilcoxon rank sum test for continuous variables; p&#160;&lt;&#160;0.05. GCSE &#8211; General Certificate of Secondary Education, A-levels &#8211; Advanced Level qualifications, NVQs &#8211; National Vocational Qualifications, BTECs &#8211; Business and Technology Education Council qualifications.</p></fn></table-wrap-foot></table-wrap></p><p>Drug-specific analysis showed consistent age and sex differences between those who had and had not tried specific SSRIs (e.g. Citalopram: Not tried vs. Tried, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S2</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Table&#160;S6</uri>). Participants who tried citalopram, fluoxetine, and sertraline were generally younger than those who had not tried the respective drug (citalopram: 52.9 &#177; 7.3 vs. 51.9 &#177; 7.3 years, <italic toggle="yes">p</italic> = 5.1 &#215; 10<sup>&#8722;22</sup>; fluoxetine: 52.8 &#177; 7.3 vs. 52.1 &#177; 7.1 years, <italic toggle="yes">p</italic> = 3.7 &#215; 10<sup>&#8722;12</sup>; sertraline: 52.7 &#177; 7.1 vs. 51.9 &#177; 7.5 years, <italic toggle="yes">p</italic> = 9.4 &#215; 10<sup>&#8722;16</sup>); while paroxetine users were older (52.4 &#177; 7.3 vs. 53.2 &#177; 7.2 years, <italic toggle="yes">p</italic> = 3.4 &#215; 10<sup>&#8722;08</sup>).</p><p>Further demographic insights revealed fluoxetine users were more likely to be from less deprived neighborhoods and have a university degree (&#8722;1.5 &#177; 3 vs. &#8722;1.3 &#177; 3, <italic toggle="yes">p</italic> = 3.6 &#215; 10<sup>&#8722;03</sup><sub>;</sub> University degree: 43% vs. 45%, <italic toggle="yes">p</italic> = 5.6 &#215; 10<sup>&#8722;04</sup>), while sertraline users were less educated (45% vs. 41%, <italic toggle="yes">p</italic> = 1.6 &#215; 10<sup>&#8722;04</sup>), more likely to be non-white (White: 99% vs. 98%, <italic toggle="yes">p</italic> = 0.02), and from lower-income groups (&lt;&#163;18 K: 16% vs. 18%). Paroxetine users had lower incomes (&lt;&#163;18 K: 16% vs. 18%, <italic toggle="yes">p</italic> = 2.2 &#215; 10<sup>&#8722;04</sup>) but were more educated (University degree: 43% vs. 51%, <italic toggle="yes">p</italic> = 3.2 &#215; 10<sup>&#8722;13</sup>).</p></sec><sec sec-type="other" id="sec20"><title>Antidepressant exposure and response</title><p>When considering definitive responses to whether drugs had worked for participants (&#8220;Y&#8221;/&#8220;N&#8221;), 79.6% felt SSRIs made them &#8220;<italic toggle="yes">feel better</italic>&#8221; (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S1</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Table&#160;S7</uri>). This positive response was consistent across individual drugs, but rates varied by drug (&#967;<sup>2</sup> = 73.28, <italic toggle="yes">p</italic> = 8.5 &#215; 10<sup>&#8722;16</sup>), highest for citalopram (82.8%) and lowest for paroxetine (76.8%) (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S1</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Table&#160;S8</uri>).</p></sec><sec sec-type="other" id="sec21"><title>Factors associated with treatment response</title><sec sec-type="other" id="sec22"><title>Sociodemographic factors</title><p>In univariable analysis, the strongest factor (largest effect size and lowest <italic toggle="yes">p</italic>-value) associated with SSRI non-response across all phenotypes was alcohol and illicit drug use, followed by male gender, higher neighborhood deprivation, current smoking, lower income (&lt;&#163;18 K), previous drinking, and mixed ethnicity (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S2</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Table&#160;S1</uri>).</p><p>For the SSRI response outcome, 17,789 participants had complete data across included predictors. Multivariable logistic regression showed alcohol and illicit drug use, age, gender, and income remained significant predictors of SSRI non-response after multiple testing adjustment (<xref rid="fig2" ref-type="fig">Figure 2</xref>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S2</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Table&#160;S2</uri>). Specifically, alcohol and illicit drug use was associated with higher odds of reporting that SSRIs did not improve symptoms (OR = 1.59, 95%CI = 1.44&#8211;1.75, <italic toggle="yes">p</italic> = 2.23 &#215; 10<sup>&#8722;20</sup>) &#8211; that is, those who used alcohol and illicit drugs to manage their cardinal MDD symptoms were more likely to report an SSRI did not help them improve (&#8220;feel better&#8221;) compared to those who did not use alcohol and illicit drugs. Male gender (OR = 1.25, 95%CI = 1.15&#8211;1.36, <italic toggle="yes">p</italic> = 8.29 &#215; 10<sup>&#8722;08</sup>) and lower income (&#163;18 K) relative to the median income (&#163;30 K&#8211;&#163;52 K) (OR = 1.35, 95%CI = 1.20&#8211;1.52, <italic toggle="yes">p</italic> = 4.22 &#215; 10<sup>&#8722;07</sup>) were also linked to non-response. Compared to older individuals, younger age was associated with a decreased likelihood of SSRI non-response (OR = 0.87, 95%CI = 0.84&#8211;0.91, <italic toggle="yes">p</italic> = 8.92 &#215; 10<sup>&#8722;11</sup>), with the odds of non-response decreasing by 13% for each additional year.<fig position="float" id="fig2" orientation="portrait"><label>Figure 2.</label><caption><p>Sociodemographic factors associated with self-reported SSRI non-response in UKB. <italic toggle="yes">N</italic>&#160;=&#160;17,479. Odds ratios, 95% confidence intervals significance, controlling for all other factors. Significance based on multiple testing correction (<italic toggle="yes">P</italic>&#160;&lt;&#160;0.0009). Ethnic background has been excluded from this figure because of wide confidence intervals (see <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S2</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Table&#160;S1</uri>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0033291725000388_fig2.jpg"/></fig></p><p>Neighborhood deprivation, smoking status, drinking status, and educational attainment were nominally significant but did not meet the multiple testing threshold (<italic toggle="yes">p</italic> &lt; 0.0009). These patterns were consistent in the conservative-SSRI outcome (<italic toggle="yes">N</italic> = 16,259) where TDI was also associated with non-response (OR = 1.08, 95%CI = 1.03&#8211;1.13, <italic toggle="yes">p</italic> = 8.71 &#215; 10<sup>&#8722;04</sup>).</p><p>At the drug-specific level (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S1</uri>), treatment response associations largely mirrored the broader SSRI pattern, with some variation. Multivariable analysis showed that after correcting for multiple testing (<italic toggle="yes">p</italic> &lt; 0.0002), alcohol and illicit drug use was the strongest predictor of non-response to citalopram (<italic toggle="yes">N</italic> = 7524) (OR = 1.53, 95%CI = 1.31&#8211;1.79, <italic toggle="yes">p</italic> = 5.78 &#215; 10<sup>&#8722;08</sup>), while male gender was the greatest predictor for fluoxetine (<italic toggle="yes">N</italic> = 7621) (OR = 1.55, 95%CI = 1.37&#8211;1.75, <italic toggle="yes">p</italic> = 2.63 &#215; 10<sup>&#8722;12</sup>). Younger age was significantly associated with response to citalopram (OR = 0.86, 95%CI = 1.81&#8211;0.92, <italic toggle="yes">p</italic> = 9.03 &#215; 10<sup>&#8722;05</sup>), and to sertraline (OR = 0.86, 95%CI = 1.80&#8211;0.93, <italic toggle="yes">p</italic> = 9.03 &#215; 10<sup>&#8722;05</sup>).</p></sec><sec sec-type="other" id="sec23"><title>Clinical factors</title><p>In univariable analysis, SSRI non-response was associated with a later age at the first episode, multiple episodes, worst episode duration exceeding 2 years, lack of mood-brightening during the worst episode, difficulty coping with rejection, feelings of heavy limbs, worthlessness, and thoughts of death. Non-response associations were similar and consistent at the SSRI and drug-specific level (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S2</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Table&#160;S3</uri>).</p><p>In multivariable analyses (<xref rid="fig3" ref-type="fig">Figure 3</xref>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S2</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Table&#160;S4</uri>), SSRI non-response (<italic toggle="yes">N</italic> = 9418) was significantly associated with a worst episode lasting more than 2 years (OR = 1.93, 95%CI = 1.65&#8211;2.26, <italic toggle="yes">p</italic> = 3.87 &#215; 10<sup>&#8722;16</sup>) and no brightening of mood in response to positive events during the worst episode of depression (OR = 1.35, 95%CI = 1.21&#8211;1.52, <italic toggle="yes">p</italic> = 2.37 &#215; 10<sup>&#8722;07</sup>). In sensitivity analyses, the worst episode duration over 2 years was associated with non-response for each drug (citalopram: OR = 2.11, 95%CI = 1.64&#8211;2.72, <italic toggle="yes">p</italic> = 8.50 &#215; 10<sup>&#8722;09</sup>; fluoxetine: OR = 1.65, 95%CI = 1.3&#8211;2.1, <italic toggle="yes">p</italic> = 4.29 &#215; 10<sup>&#8722;05</sup>; paroxetine: OR = 2.43, 95%CI = 1.55&#8211;3.81, <italic toggle="yes">p</italic> = 1.02 &#215; 10<sup>&#8722;04</sup>; sertraline: OR = 1.97, 95%CI = 1.49&#8211;2.61, <italic toggle="yes">p</italic> = 1.68 &#215; 10<sup>&#8722;06</sup>).<fig position="float" id="fig3" orientation="portrait"><label>Figure 3.</label><caption><p>Clinical factors associated with self-reported SSRI non-response in UKB. Odds ratios, 95% confidence intervals significance, controlling for all other factors (<italic toggle="yes">N</italic>&#160;=&#160;9418. Analyses have been restricted to those of white ethnic background and adjusted for age and sex. Significance based on multiple testing correction (<italic toggle="yes">P</italic>&#160;&lt;&#160;0.0009).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0033291725000388_fig3.jpg"/></fig></p></sec><sec sec-type="other" id="sec24"><title>Genetic factors</title><sec sec-type="other" id="sec25"><title>CYP2C19 metabolizer status</title><p>Our study included 18,992 unrelated individuals of European ancestry with available CYP2C19 genotype and phenotype data. The largest group was CYP2C19 normal metabolizers (NM) (7507, 39.5%), followed by rapid metabolizers (RM) (5155, 27.1%) and intermediate metabolizers (IM) (4943, 26.0%). As expected, poor metabolizers (PM) (443, 2.3%) and ultra-rapid (UM) (930, 4.9%) were less common, with 0.1% having indeterminate status. Similar proportions were observed at the drug-specific level (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S1</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Table&#160;S11</uri>).</p><p>Association analyses between self-reported SSRI response and CYP2C19 metabolizer status showed that those with a PM status had nominally significant higher likelihood of non-response compared to NM (OR = 1.31, 95%CI = 1.05&#8211;1.65, <italic toggle="yes">p</italic> = 1.77 &#215; 10<sup>&#8722;02</sup>); this was mirrored in the conservative approach but with increased significance (OR = 1.41, 95%CI = 1.09&#8211;1.83, <italic toggle="yes">p</italic> = 8.57 &#215; 10<sup>&#8722;03</sup>). A similar association was observed for fluoxetine (OR = 1.42, 95%CI = 1.02&#8211;1.97, <italic toggle="yes">p</italic> = 3.50 &#215; 10<sup>&#8722;02</sup>) (<xref rid="fig4" ref-type="fig">Figure 4A</xref>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S2</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Table&#160;S5</uri>). Drug-specific associations showed nominally significant lower odds of self-reported non-response among IM using fluoxetine (OR = 0.87, 95%CI = 0.76 = 0.99, <italic toggle="yes">p</italic> = 3.87 &#215; 10<sup>&#8722;02</sup>) and higher odds of non-response among UM taking paroxetine (OR = 1.70, 95%CI = 1.08&#8211;2.68, <italic toggle="yes">p</italic> = 2.29 &#215; 10<sup>&#8722;02</sup>). No significant associations were noted among citalopram and sertraline users. None of the identified associations survived multiple testing correction.<fig position="float" id="fig4" orientation="portrait"><label>Figure 4.</label><caption><p>Genetic predictors of self-reported antidepressant non-response in UKB. (A) Inferred CYP2C19 metabolizer status associated with self-reported antidepressant non-response in UKB. Forest plots depict odds ratios and 95% confidence intervals for the association between metabolizer category (compared to normal) and treatment non-response (blue markers) for SSRIs and specific SSRIs (Citalopram, Fluoxetine, Paroxetine, Sertraline). Inferred metabolizer status levels are Poor, Normal (reference), Intermediate, Rapid, and Ultra-rapid. Significance: <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05; displayed <italic toggle="yes">p</italic> values indicate significance persisted after multiple testing corrections (<italic toggle="yes">P</italic>&#160;&lt;&#160;0.0002). (B) Psychiatric and antidepressant response PGS associated with self-reported antidepressant non-response in UKB. The association analyses between SSRIs and specific SSRIs (Citalopram, Fluoxetine, Paroxetine, Sertraline) and self-reported antidepressant outcomes and various mental health condition and treatment PGS. PGS include DEPR: Depression, ADHD: Attention Deficit Hyperactivity Disorder, AUTI: Autism, BIPO: Bipolar Disorder, SCHI: Schizophrenia. ADperc: Percentage improvement, ADnorem: AD non-remission. Significance: <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05; displayed <italic toggle="yes">p</italic> values indicate significance persisted after multiple testing corrections (<italic toggle="yes">P</italic>&#160;&lt;&#160;0.0002).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="S0033291725000388_fig4.jpg"/></fig></p></sec><sec sec-type="other" id="sec26"><title>Polygenic scores</title><p>We tested for the association between self-reported SSRI response and PGS for five psychiatric conditions and two antidepressant response measures (<xref rid="fig4" ref-type="fig">Figure 4B</xref>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S2</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Table&#160;S6</uri>). For psychiatric traits, SSRI (&#8220;SSRI&#8221; in <xref rid="fig4" ref-type="fig">Figure 4</xref>) non-response was nominally associated with all psychiatric condition PGS: depression (OR = 1.08, 95%CI = 1.04&#8211;1.12, <italic toggle="yes">p</italic> = 3.37 &#215; 10<sup>&#8722;05</sup>), attention deficit hyperactivity disorder (ADHD) (OR = 1.06, 95%CI = 1.02&#8211;1.10, <italic toggle="yes">p</italic> = 1.06 &#215; 10<sup>&#8722;03</sup>), autism (OR = 1.05, 95%CI = 1.01&#8211;1.09, <italic toggle="yes">p</italic> = 7.42 &#215; 10<sup>&#8722;03</sup>), bipolar (OR = 1.04, 95%CI = 1.01&#8211;1.08, <italic toggle="yes">p</italic> = 2.06 &#215; 10<sup>&#8722;02</sup>), and schizophrenia (OR = 1.06, 95%CI = 1.02&#8211;1.10, <italic toggle="yes">p</italic> = 1.53 &#215; 10<sup>&#8722;03</sup>). In each case, higher genetic liability to the condition (higher PGS) corresponded with a lack of response to SSRIs (6&#8211;8% increase in the odds of non-response per SD increase of PGS). The phenotypic variance explained (<italic toggle="yes">R2</italic>) for each of these PGS with SSRI non-response ranged between 0.07% and 0.16% (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Data&#160;S1</uri>, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">Supplementary&#160;Figure&#160;S4</uri>). Only the association with the PGS for depression survived multiple testing corrections. For the antidepressant response PGS (non-remission (ADnorem) and percentage improvement (ADperc), no significant findings were noted.</p><p>Sensitivity analyses similarly showed the conservative approach similarly revealed all disorder PGS to be nominally associated with non-response but only the PGS for ADHD survived multiple testing correction. In the drug-specific non-response analysis, other disorders showed nominal significance (e.g. depression and bipolar PGS with citalopram and fluoxetine; and depression and ADHD PGS with sertraline) (<xref rid="fig4" ref-type="fig">Figure 4B</xref>). For the antidepressant response PGS (non-remission [ADnorem] and percentage improvement [ADperc]), a nominally significant finding was noted between fluoxetine non-response and the non-remission PGS (<italic toggle="yes">R</italic><sup>2</sup> = 0.235, OR = 0.93, 95%CI = 0.88&#8211;0.98, <italic toggle="yes">p</italic> = 4.80 &#215; 10<sup>&#8722;03</sup>). Across all drugs, none of these findings persisted following multiple testing correction.</p></sec></sec></sec></sec><sec sec-type="discussion" id="sec27"><title>Discussion</title><p>Antidepressants, particularly SSRIs, are widely prescribed, yet remission rates remain low, and few risk factors guide personalized prescribing. A major challenge in identifying factors to predict treatment is the absence of response measures that are scalable across large sample sizes. Several large studies have applied patient self-report questionnaires on response, asking a single, simple question about whether an antidepressant has &#8216;helped&#8217;. In this article, we assessed the UKB&#8217;s antidepressant self-report data to identify clinical, sociodemographic, and genetic factors associated with a lack of response to SSRIs, aiming to demonstrate that this self-reported outcome is a valid measure of antidepressant response.</p><p>In UKB, 75% of participants reported a positive SSRI response, substantially higher than the 35% remission rate noted in trials (Rush et al., <xref rid="r47" ref-type="bibr">2004</xref>). This discrepancy may reflect the question wording (&#8220;Has &lt;drugname&gt; helped you feel better&#8221; with possible responses of &#8220;Yes, at least a little,&#8221; and &#8220;No&#8221;), which is not synonymous with remission. This is a lower threshold than the criteria used for remission in clinical trials, where depression symptoms must fall below the diagnostic threshold for depression (Stone et al., <xref rid="r56" ref-type="bibr">2022</xref>). Here, the antidepressant may be providing symptom reduction rather than remission and may also coincide with the natural progression of an episode. The perception of antidepressant efficacy based on improved daily functioning aligns with findings that patients prioritize a return to normal functioning as much as the absence of symptoms (Zimmerman et al., <xref rid="r69" ref-type="bibr">2006</xref>). Additionally, unlike the 8&#8211;12-week assessment span of clinical trials, the UKB questionnaire uses a retrospective measure based on the full length of an SSRI treatment period, suggesting while self-reported response may not adequately gauge &#8216;remission&#8217; status, it could reflect improvements in personal functioning.</p><p>For the self-reported antidepressant response to be a valuable phenotype, a deeper understanding of factors associated with a negative response is needed. Our analysis revealed significant associations with sociodemographic, clinical, and genetic variables, with consistent direction and effect sizes across SSRIs. Non-response to SSRIs was associated with being male, older age, having a lower income and alcohol and illicit drug use. These factors largely align with clinical trial predictors while also highlighting real-world influences like substance use.</p><p>For example, males exhibited lower response rates, consistent with some clinical studies (Gibiino, Marsano, &amp; Serretti, <xref rid="r18" ref-type="bibr">2014</xref>; Serretti, Gibiino, &amp; Drago, <xref rid="r52" ref-type="bibr">2011</xref>; Trivedi et al., <xref rid="r59" ref-type="bibr">2006</xref>), although no difference was found in iSPOT-D (Saveanu et al., <xref rid="r51" ref-type="bibr">2015</xref>) or a meta-analysis of Randomized Control Trials (RCTs) (Cuijpers et al., <xref rid="r10" ref-type="bibr">2014</xref>). Lower-income has been associated with reduced treatment response in a recent RCT (Mills et al., <xref rid="r35" ref-type="bibr">2022</xref>), and in STAR*D, where reduced adherence and shorter treatment duration were found in lower-income groups, even when controlled for treatment access and level of care (Jakubovski &amp; Bloch, <xref rid="r26" ref-type="bibr">2014</xref>). Younger age at UKB recruitment was associated with better SSRI response; similar to other research (Uher et al., <xref rid="r60" ref-type="bibr">2009</xref>). This also aligns with data suggesting depression is more chronic and antidepressants less effective in older patients (Haigh, Bogucki, Sigmon, &amp; Blazer, <xref rid="r20" ref-type="bibr">2018</xref>; Strawn et al., <xref rid="r57" ref-type="bibr">2023</xref>). However, no information on the age at antidepressant use is available in UKB.</p><p>Clinical associations of poor SSRI response in UKB were persistent low mood and long depressive episodes (&#8805;2 years), consistent with findings that greater severity (Rush et al., <xref rid="r47" ref-type="bibr">2004</xref>) and melancholic depression hinder recovery and reduce perceived antidepressant efficacy (Valerio, Szmulewicz, &amp; Martino, <xref rid="r63" ref-type="bibr">2018</xref>). Hieronymus et al. emphasize targeting low mood to improve MDD treatment outcomes; their SSRI RCT reanalysis found higher rates of efficacy when focusing on mood improvements (where 91% of participants showed efficacy) than with HDRS-17 scores (efficacy in 44%) (Hieronymus, Emilsson, Nilsson, &amp; Eriksson, <xref rid="r22" ref-type="bibr">2016</xref>). Higher severity of depression, as assessed by the proxy measures of a long-duration episode (&#8805;2 years) and by a higher genetic liability for MDD, was correlated with non-response. In clinical trials, more severe depression has a better response (compared to placebo), but the different measurements of response and severity make a direct comparison of these results difficult.</p><p>Our study provides insights into the genetic basis for SSRI response. Higher genetic liability for depression, and attention-deficit/hyperactivity disorder (ADHD) was associated with poorer self-reported antidepressant response, consistent with previous research (Pain et al., <xref rid="r41" ref-type="bibr">2022</xref>). The association between higher PGS and treatment non-response is consistent with clinical studies that link higher depression PGS to increased side effects, such as dizziness and reduced sexual desire, which may impact treatment effectiveness by hindering effective dosage maintenance (Campos et al., <xref rid="r6" ref-type="bibr">2021</xref>). The link between genetic liability for ADHD in UKB may reflect missed diagnosis in this older age group. A recent study reported that 28% of adults referred for mood and anxiety assessments had undiagnosed ADHD, with the number of prior SSRI prescriptions being a significant predictor (Sternat, Mohammed, &amp; Furtado, <xref rid="r55" ref-type="bibr">2016</xref>).</p><p>CYP2C19 metabolizer status proportions in our study were highly concordant with other studies in European populations (Campos et al., <xref rid="r5" ref-type="bibr">2022</xref>; Ionova et al., <xref rid="r24" ref-type="bibr">2020</xref>). A nominally significant positive association between poor metabolizer (PM) status and SSRI non-response was observed. This association was mirrored in the conservative approach and amongst fluoxetine users, but no association survived multiple testing corrections. This finding contrasts with previous studies reporting increased efficacy of SSRIs, such as citalopram and sertraline, among PMs (Fabbri et al., <xref rid="r13" ref-type="bibr">2018</xref>; Li et al., <xref rid="r32" ref-type="bibr">2024</xref>). Authors suggest that the broad therapeutic windows of these medications may limit the influence of CYP2C19 polymorphisms on treatment response (Campos et al., <xref rid="r5" ref-type="bibr">2022</xref>). Also, CYP2C19 is not the sole enzyme involved in SSRI metabolism: while it plays a primary role in metabolizing citalopram, its role is less significant for sertraline, fluoxetine, and paroxetine (Li et al., <xref rid="r32" ref-type="bibr">2024</xref>; Obach, Cox, &amp; Tremaine, <xref rid="r38" ref-type="bibr">2005</xref>; Yuce-Artun et al., <xref rid="r68" ref-type="bibr">2016</xref>). The non-response for PMs may also reflect high adverse events in this group, where participants stopped taking the drug due to severe side effects (and so report &#8216;no&#8217; that the drug did not help them). In contrast, in clinical trials, only PMs reaching the end of the trial period are included, which may exclude those with severe adverse events.</p><p>At the drug-specific level, the nominal significance of PM status among fluoxetine&#8217;s users may be in part due to fluoxetine&#8217;s relatively long half-life, which averages 2&#8211;4 days for the parent compound and extends to 7&#8211;15 days for its active metabolite, norfluoxetine (Hiemke &amp; H&#228;rtter, <xref rid="r21" ref-type="bibr">2000</xref>). In contrast, citalopram has a much shorter half-life of approximately 36 h (Hiemke &amp; H&#228;rtter, <xref rid="r21" ref-type="bibr">2000</xref>). The significantly longer half-life of fluoxetine can lead to substantial drug accumulation, particularly in poor metabolizers, potentially increasing the likelihood of side effects and influencing treatment adherence and response. Non-response to paroxetine in UM suggests insufficient drug levels to achieve therapeutic effects, necessitating higher doses (Li et al., <xref rid="r32" ref-type="bibr">2024</xref>; Wong et al., <xref rid="r65" ref-type="bibr">2023</xref>).</p><p>Mental health research increasingly recognizes the importance of patient perspectives and priorities, but there is a paucity of studies on patients&#8217; views on antidepressant use and response. The Wellcome Trust has prioritized patient and public involvement (PPI) in all their funded Mental Health studies (Wellcome Trust, <xref rid="r64" ref-type="bibr">n.d.</xref>), and our Antidepressant Medications: Biology, Exposure, and Response (AMBER) research program has ongoing research to understand the priorities of those taking antidepressants.</p><p>Self-report questionnaires from the UKB provide novel and rich data to better understand patient perspectives, which can, in turn, help more accurately measure outcomes and tailor management pathways. Despite its potential utility, additional measures, such as a refined scale that captures multiple types of positive responses, could further enhance our understanding of what constitutes meaningful recovery for patients.</p><p>This study has many strength in its patient-centered approach, providing valuable information on antidepressant treatment from the patient&#8217;s perspective. This easily collected phenotype is available in large numbers in the UKB, the Australian Genetics of Depression Study (AGDS; Byrne et al., <xref rid="r4" ref-type="bibr">2020</xref>), and Genetic Links to Anxiety and Depression (GLAD; Davies et al., <xref rid="r11" ref-type="bibr">2019</xref>; Koch et al., <xref rid="r31" ref-type="bibr">2024</xref>). Our study shows good alignment of sociodemographic and clinical risk factors between the UKB self-report response and clinical trial research in antidepressants, suggesting both measures pick up common information on response and non-response. This provides an important source of information to expand sample sizes for research into the genetic underpinnings of antidepressant response. Differences between clinician-rated and self-rated measures suggest patients have unique perspectives on treatment outcomes, which are critical to a complete assessment of depression (Campos et al., <xref rid="r5" ref-type="bibr">2022</xref>; Ramanuj, Ferenchick, &amp; Pincus, <xref rid="r45" ref-type="bibr">2019</xref>; Uher et al., <xref rid="r61" ref-type="bibr">2012</xref>; Zimmerman et al., <xref rid="r69" ref-type="bibr">2006</xref>).</p><p>While our study offers valuable insights into antidepressant response, it has several limitations. The analyses were based on UKB, which has better-than-average socioeconomic circumstances than the general population, potentially limiting the generalizability of the findings and underestimating the impact of low income. The reliance on retrospective self-reports is subject to recall bias and inaccuracies &#8211; participants may either underreport or overreport their past symptoms and healthcare experiences. Sociodemographic variables were reported at the time of the baseline UKB questionnaire, not during the participant&#8217;s worst depressive episode, complicating factor assessment. Further limitations of this analysis include its focus on those who have tried SSRIs, potentially resulting in a dataset that may not fully capture the diversity of antidepressant usage amongst the UK population. Moreover, the inability to determine the timing of antidepressant exposure and whether the drugs were used independently or concurrently, or whether they were prescribed for different episodes or had overlapping use, complicates the interpretation of treatment patterns and outcomes. We are unable to dissect the natural disorder course from the antidepressant response, and some patients responding that the drug helped them may have had a similar recovery trajectory without an antidepressant.</p><p>It is important to note that many individuals reporting improvement in response to antidepressants may be reacting to nonspecific aspects of treatment rather than the pharmacological effects of antidepressants, as reflected in high placebo response rates in trials. While metabolizer status is likely to reflect drug-specific effects, other predictors (e.g. low income) may identify individuals at greater risk of poor outcomes irrespective of the specific treatment received. This distinction between predictors of response and true moderators highlights a key limitation and underscores the need for further research in this area.</p></sec><sec sec-type="conclusions" id="sec28"><title>Conclusion</title><p>Self-reported antidepressant response outcome in UK Biobank is influenced by sociodemographic, clinical characteristics, and common genetic variation, similar to clinical response measures. Despite the higher frequency of positive response outcomes compared to clinical trials, these retrospective self-report outcomes replicate known associations with current antidepressant treatment outcomes. This suggests that self-reported outcomes, while measuring a positive response that is not equivalent to remission, capture meaningful aspects of antidepressant effectiveness, particularly from the patient&#8217;s perspective.</p></sec><sec sec-type="supplementary-material" id="sec33"><title>Supporting information</title><supplementary-material id="sm01" position="float" content-type="local-data" orientation="portrait"><caption><title>Kamp et al. supplementary material 1</title><p>Kamp et al. supplementary material</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="S0033291725000388sup001.docx" id="d67e1568" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="sm02" position="float" content-type="local-data" orientation="portrait"><caption><title>Kamp et al. supplementary material 2</title><p>Kamp et al. supplementary material</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="S0033291725000388sup002.xlsx" id="d67e1573" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>We gratefully acknowledge the time and attention of the participants who generously provided data and donated their samples to the UK Biobank. UKB analysis conducted under project 82087. This study made use of the King&#8217;s Computational Research, Engineering and Technology Environment (CREATE) provided by e-Research King&#8217;s College London (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://docs.er.kcl.ac.uk/">https://docs.er.kcl.ac.uk/</uri>). This publication is the study of the authors and CML will serve as guarantor for the contents of this article.</p></ack><sec sec-type="supplementary-material" id="nts1"><title>Supplementary material</title><p>The supplementary material for this articlecan be found at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://doi.org/10.1017/S0033291725000388">http://doi.org/10.1017/S0033291725000388</uri>.</p></sec><sec sec-type="data-availability" id="sec29"><title>Data availability statement</title><p>Code relating to the analyses in this article is available on GitHub (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/michellekamp/Predictors-of-Self-reported-SSRI-response">https://github.com/michellekamp/Predictors-of-Self-reported-SSRI-response</uri>) and the GenoPred Pipeline code is available from the GenoPred GitHub Code Repository (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://opain.github.io/GenoPred/">https://opain.github.io/GenoPred/</uri>). Summary statistics from the PGC are available online (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pgc.unc.edu/for-researchers/download-results/">https://pgc.unc.edu/for-researchers/download-results/</uri>). Data from the UK Biobank (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ukbiobank.ac.uk">https://www.ukbiobank.ac.uk</uri>) are available to bona fide researchers upon application.</p></sec><sec sec-type="funding-statement" id="sec30"><title>Funding statement</title><p>This study was supported by the Wellcome Trust (grant number 226770/Z/22/Z). OP is supported by a Sir Henry Wellcome Postdoctoral Fellowship [222811/Z/21/Z]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study represents independent research part funded by the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King&#8217;s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care in the UK. The funders had no role in the study&#8217;s design; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</p></sec><sec sec-type="COI-statement" id="sec31"><title>Competing interests</title><p>CML sits on the Myriad Neuroscience Scientific Advisory Board and is a Key Opinion Leader for UCB Pharma. OP provides consultancy services for UCB Pharma. The remaining authors declare that there are no competing interests.</p></sec><sec sec-type="other" id="sec32"><title>Ethical standard</title><p>The authors assert that all procedures contributing to this study comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.</p></sec><ref-list id="refs1" content-type="normal"><title>References</title><ref id="r1"><mixed-citation publication-type="journal" id="ref1"><string-name name-style="western"><surname>Abdoli</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Salari</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Darvishi</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Jafarpour</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Solaymani</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Mohammadi</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal> (<year>2022</year>). <article-title>The global prevalence of major depressive disorder (MDD) among the elderly: A systematic review and meta-analysis</article-title>. <source>Neuroscience and Biobehavioral Reviews</source>, <volume>132</volume>, <fpage>1067</fpage>&#8211;<lpage>1073</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neubiorev.2021.10.041</pub-id><pub-id pub-id-type="pmid">34742925</pub-id></mixed-citation></ref><ref id="r2"><mixed-citation publication-type="journal" id="ref2"><string-name name-style="western"><surname>Allen</surname>, <given-names>N. E.</given-names></string-name>, <string-name name-style="western"><surname>Sudlow</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Peakman</surname>, <given-names>T.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Collins</surname>, <given-names>R.</given-names></string-name> (<year>2014</year>). <article-title>UK Biobank data: Come and get it</article-title>. <source>Science Translational Medicine</source>, <volume>6</volume>(<issue>224</issue>), <fpage>224ed4</fpage>&#8211;<lpage>224ed4</lpage>. doi: <pub-id pub-id-type="doi">10.1126/scitranslmed.3008601</pub-id><pub-id pub-id-type="pmid">24553384</pub-id></mixed-citation></ref><ref id="r3"><mixed-citation publication-type="journal" id="ref3"><string-name name-style="western"><surname>Bauer</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Severus</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>M&#246;ller</surname>, <given-names>H.-J.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Young</surname>, <given-names>A. H.</given-names></string-name> (<year>2017</year>). <article-title>Pharmacological treatment of unipolar depressive disorders: Summary of WFSBP guidelines</article-title>. <source>International Journal of Psychiatry in Clinical Practice</source>, <volume>21</volume>(<issue>3</issue>), <fpage>166</fpage>&#8211;<lpage>176</lpage>. doi: <pub-id pub-id-type="doi">10.1080/13651501.2017.1306082</pub-id><pub-id pub-id-type="pmid">28367707</pub-id></mixed-citation></ref><ref id="r4"><mixed-citation publication-type="journal" id="ref4"><string-name name-style="western"><surname>Byrne</surname>, <given-names>E. M.</given-names></string-name>, <string-name name-style="western"><surname>Kirk</surname>, <given-names>K. M.</given-names></string-name>, <string-name name-style="western"><surname>Medland</surname>, <given-names>S. E.</given-names></string-name>, <string-name name-style="western"><surname>McGrath</surname>, <given-names>J. J.</given-names></string-name>, <string-name name-style="western"><surname>Colodro-Conde</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Parker</surname>, <given-names>R.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>). <article-title>Cohort profile: The Australian genetics of depression study</article-title>. <source>BMJ Open</source>, <volume>10</volume>(<issue>5</issue>), <fpage>e032580</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmjopen-2019-032580</pub-id><pub-id pub-id-type="pmcid">PMC7259831</pub-id><pub-id pub-id-type="pmid">32461290</pub-id></mixed-citation></ref><ref id="r5"><mixed-citation publication-type="journal" id="ref5"><string-name name-style="western"><surname>Campos</surname>, <given-names>A. I.</given-names></string-name>, <string-name name-style="western"><surname>Byrne</surname>, <given-names>E. M.</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname>, <given-names>B. L.</given-names></string-name>, <string-name name-style="western"><surname>Wray</surname>, <given-names>N. R.</given-names></string-name>, <string-name name-style="western"><surname>Lind</surname>, <given-names>P. A.</given-names></string-name>, <string-name name-style="western"><surname>Licinio</surname>, <given-names>J.</given-names></string-name>, <etal>et al.</etal> (<year>2022</year>). <article-title>Impact of CYP2C19 metaboliser status on SSRI response: A retrospective study of 9500 participants of the Australian Genetics of Depression Study</article-title>. <source>The Pharmacogenomics Journal</source>, <volume>22</volume>(<issue>2</issue>), <fpage>130</fpage>&#8211;<lpage>135</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41397-022-00267-7</pub-id><pub-id pub-id-type="pmid">35094016</pub-id><pub-id pub-id-type="pmcid">PMC8975743</pub-id></mixed-citation></ref><ref id="r6"><mixed-citation publication-type="journal" id="ref6"><string-name name-style="western"><surname>Campos</surname>, <given-names>A. I.</given-names></string-name>, <string-name name-style="western"><surname>Mulcahy</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Thorp</surname>, <given-names>J. G.</given-names></string-name>, <string-name name-style="western"><surname>Wray</surname>, <given-names>N. R.</given-names></string-name>, <string-name name-style="western"><surname>Byrne</surname>, <given-names>E. M.</given-names></string-name>, <string-name name-style="western"><surname>Lind</surname>, <given-names>P. A.</given-names></string-name>, <etal>et al.</etal> (<year>2021</year>). <article-title>Understanding genetic risk factors for common side effects of antidepressant medications</article-title>. <source>Communications Medicine</source>, <volume>1</volume>, <fpage>45</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s43856-021-00046-8</pub-id><pub-id pub-id-type="pmid">35602235</pub-id><pub-id pub-id-type="pmcid">PMC9053224</pub-id></mixed-citation></ref><ref id="r7"><mixed-citation publication-type="journal" id="ref7"><string-name name-style="western"><surname>Cipriani</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Furukawa</surname>, <given-names>T. A.</given-names></string-name>, <string-name name-style="western"><surname>Salanti</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Chaimani</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Atkinson</surname>, <given-names>L. Z.</given-names></string-name>, <string-name name-style="western"><surname>Ogawa</surname>, <given-names>Y.</given-names></string-name>, <etal>et al.</etal> (<year>2018</year>). <article-title>Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis</article-title>. <source>Focus (American Psychiatric Publishing)</source>, <volume>16</volume>(<issue>4</issue>), <fpage>420</fpage>&#8211;<lpage>429</lpage>. doi: <pub-id pub-id-type="doi">10.1176/appi.focus.16407</pub-id><pub-id pub-id-type="pmid">32021580</pub-id><pub-id pub-id-type="pmcid">PMC6996085</pub-id></mixed-citation></ref><ref id="r8"><mixed-citation publication-type="journal" id="ref8"><string-name name-style="western"><surname>Cleare</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Pariante</surname>, <given-names>C. M.</given-names></string-name>, <string-name name-style="western"><surname>Young</surname>, <given-names>A. H.</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname>, <given-names>I. M.</given-names></string-name>, <string-name name-style="western"><surname>Christmas</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Cowen</surname>, <given-names>P. J.</given-names></string-name>, <etal>et al.</etal> (<year>2015</year>). <article-title>Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines</article-title>. <source>Journal of Psychopharmacology</source>, <volume>29</volume>(<issue>5</issue>), <fpage>459</fpage>&#8211;<lpage>525</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0269881115581093</pub-id><pub-id pub-id-type="pmid">25969470</pub-id></mixed-citation></ref><ref id="r9"><mixed-citation publication-type="journal" id="ref9"><string-name name-style="western"><surname>Cui</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Li</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname>, <given-names>W.</given-names></string-name>, <etal>et al.</etal> (<year>2024</year>). <article-title>Major depressive disorder: Hypothesis, mechanism, prevention and treatment</article-title>. <source>Signal Transduction and Targeted Therapy</source>, <volume>9</volume>(<issue>1</issue>), <fpage>1</fpage>&#8211;<lpage>32</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-024-01738-y</pub-id><pub-id pub-id-type="pmid">38331979</pub-id><pub-id pub-id-type="pmcid">PMC10853571</pub-id></mixed-citation></ref><ref id="r10"><mixed-citation publication-type="journal" id="ref10"><string-name name-style="western"><surname>Cuijpers</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Weitz</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Twisk</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Kuehner</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Cristea</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><surname>David</surname>, <given-names>D.</given-names></string-name>, <etal>et al.</etal> (<year>2014</year>). <article-title>Gender as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression: An &#8220;individual patient data&#8221; meta-analysis</article-title>. <source>Depression and Anxiety</source>, <volume>31</volume>(<issue>11</issue>), <fpage>941</fpage>&#8211;<lpage>951</lpage>. doi: <pub-id pub-id-type="doi">10.1002/da.22328</pub-id><pub-id pub-id-type="pmid">25407584</pub-id></mixed-citation></ref><ref id="r11"><mixed-citation publication-type="journal" id="ref11"><string-name name-style="western"><surname>Davies</surname>, <given-names>M. R.</given-names></string-name>, <string-name name-style="western"><surname>Kalsi</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Armour</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname>, <given-names>I. R.</given-names></string-name>, <string-name name-style="western"><surname>McIntosh</surname>, <given-names>A. M.</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname>, <given-names>D. J.</given-names></string-name>, <etal>et al.</etal> (<year>2019</year>). <article-title>The genetic links to anxiety and depression (GLAD) study: Online recruitment into the largest recontactable study of depression and anxiety</article-title>. <source>Behaviour Research and Therapy</source>, <volume>123</volume>, <fpage>103503</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.brat.2019.103503</pub-id><pub-id pub-id-type="pmid">31715324</pub-id><pub-id pub-id-type="pmcid">PMC6891252</pub-id></mixed-citation></ref><ref id="r12"><mixed-citation publication-type="journal" id="ref12"><string-name name-style="western"><surname>Demontis</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Walters</surname>, <given-names>R. K.</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Mattheisen</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Als</surname>, <given-names>T. D.</given-names></string-name>, <string-name name-style="western"><surname>Agerbo</surname>, <given-names>E.</given-names></string-name>, <etal>et al.</etal> (<year>2019</year>). <article-title>Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder</article-title>. <source>Nature Genetics</source>, <volume>51</volume>(<issue>1</issue>), <fpage>63</fpage>&#8211;<lpage>75</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41588-018-0269-7</pub-id><pub-id pub-id-type="pmid">30478444</pub-id><pub-id pub-id-type="pmcid">PMC6481311</pub-id></mixed-citation></ref><ref id="r13"><mixed-citation publication-type="journal" id="ref13"><string-name name-style="western"><surname>Fabbri</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Tansey</surname>, <given-names>K. E.</given-names></string-name>, <string-name name-style="western"><surname>Perlis</surname>, <given-names>R. H.</given-names></string-name>, <string-name name-style="western"><surname>Hauser</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Henigsberg</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Maier</surname>, <given-names>W.</given-names></string-name>, <etal>et al.</etal> (<year>2018</year>). <article-title>Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies</article-title>. <source>European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology</source>, <volume>28</volume>(<issue>8</issue>), <fpage>945</fpage>&#8211;<lpage>954</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.euroneuro.2018.05.009</pub-id><pub-id pub-id-type="pmid">30135031</pub-id></mixed-citation></ref><ref id="r14"><mixed-citation publication-type="journal" id="ref14"><string-name name-style="western"><surname>Fanelli</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Benedetti</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Kasper</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Zohar</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Souery</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Montgomery</surname>, <given-names>S.</given-names></string-name>, <etal>et al.</etal> (<year>2021</year>). <article-title>Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder</article-title>. <source>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</source>, <volume>108</volume>, <fpage>110170</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pnpbp.2020.110170</pub-id><pub-id pub-id-type="pmid">33181205</pub-id></mixed-citation></ref><ref id="r15"><mixed-citation publication-type="journal" id="ref15"><string-name name-style="western"><surname>Fried</surname>, <given-names>E. I.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Nesse</surname>, <given-names>R. M.</given-names></string-name> (<year>2015</year>). <article-title>Depression is not a consistent syndrome: An investigation of unique symptom patterns in the STAR*D study</article-title>. <source>Journal of Affective Disorders</source>, <volume>172</volume>, <fpage>96</fpage>&#8211;<lpage>102</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jad.2014.10.010</pub-id><pub-id pub-id-type="pmid">25451401</pub-id><pub-id pub-id-type="pmcid">PMC4397113</pub-id></mixed-citation></ref><ref id="r16"><mixed-citation publication-type="journal" id="ref16"><string-name name-style="western"><surname>Garc&#237;a-Gonz&#225;lez</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Tansey</surname>, <given-names>K. E.</given-names></string-name>, <string-name name-style="western"><surname>Hauser</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Henigsberg</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Maier</surname>, <given-names>W.</given-names></string-name>, <string-name name-style="western"><surname>Mors</surname>, <given-names>O.</given-names></string-name>, <etal>et al.</etal> (<year>2017</year>). <article-title>Pharmacogenetics of antidepressant response: A polygenic approach</article-title>. <source>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</source>, <volume>75</volume>, <fpage>128</fpage>&#8211;<lpage>134</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pnpbp.2017.01.011</pub-id><pub-id pub-id-type="pmid">28159590</pub-id></mixed-citation></ref><ref id="r17"><mixed-citation publication-type="journal" id="ref17"><collab>GBD 2019 Mental Disorders Collaborators</collab>. (<year>2022</year>). <article-title>Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019</article-title>. <source>The Lancet Psychiatry</source>, <volume>9</volume>(<issue>2</issue>), <fpage>137</fpage>&#8211;<lpage>150</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S2215-0366(21)00395-3</pub-id><pub-id pub-id-type="pmid">35026139</pub-id><pub-id pub-id-type="pmcid">PMC8776563</pub-id></mixed-citation></ref><ref id="r18"><mixed-citation publication-type="journal" id="ref18"><string-name name-style="western"><surname>Gibiino</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Marsano</surname>, <given-names>A.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Serretti</surname>, <given-names>A.</given-names></string-name> (<year>2014</year>). <article-title>Specificity profile of venlafaxine and sertraline in major depression: Metaregression of double-blind, randomized clinical trials</article-title>. <source>The International Journal of Neuropsychopharmacology</source>, <volume>17</volume>(<issue>1</issue>), <fpage>1</fpage>&#8211;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S1461145713000746</pub-id><pub-id pub-id-type="pmid">23953038</pub-id></mixed-citation></ref><ref id="r19"><mixed-citation publication-type="journal" id="ref19"><string-name name-style="western"><surname>Grove</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Ripke</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Als</surname>, <given-names>T. D.</given-names></string-name>, <string-name name-style="western"><surname>Mattheisen</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Walters</surname>, <given-names>R. K.</given-names></string-name>, <string-name name-style="western"><surname>Won</surname>, <given-names>H.</given-names></string-name>, <etal>et al.</etal> (<year>2019</year>). <article-title>Identification of common genetic risk variants for autism spectrum disorder</article-title>. <source>Nature Genetics</source>, <volume>51</volume>(<issue>3</issue>), <fpage>431</fpage>&#8211;<lpage>444</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41588-019-0344-8</pub-id><pub-id pub-id-type="pmid">30804558</pub-id><pub-id pub-id-type="pmcid">PMC6454898</pub-id></mixed-citation></ref><ref id="r20"><mixed-citation publication-type="journal" id="ref20"><string-name name-style="western"><surname>Haigh</surname>, <given-names>E. A. P.</given-names></string-name>, <string-name name-style="western"><surname>Bogucki</surname>, <given-names>O. E.</given-names></string-name>, <string-name name-style="western"><surname>Sigmon</surname>, <given-names>S. T.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Blazer</surname>, <given-names>D. G.</given-names></string-name> (<year>2018</year>). <article-title>Depression among older adults: A 20-year update on five common myths and misconceptions</article-title>. <source>The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry</source>, <volume>26</volume>(<issue>1</issue>), <fpage>107</fpage>&#8211;<lpage>122</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jagp.2017.06.011</pub-id><pub-id pub-id-type="pmid">28735658</pub-id></mixed-citation></ref><ref id="r21"><mixed-citation publication-type="journal" id="ref21"><string-name name-style="western"><surname>Hiemke</surname>, <given-names>C.</given-names></string-name>, &amp; <string-name name-style="western"><surname>H&#228;rtter</surname>, <given-names>S.</given-names></string-name> (<year>2000</year>). <article-title>Pharmacokinetics of selective serotonin reuptake inhibitors</article-title>. <source>Pharmacology &amp; Therapeutics</source>, <volume>85</volume>(<issue>1</issue>), <fpage>11</fpage>&#8211;<lpage>28</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0163-7258(99)00048-0</pub-id><pub-id pub-id-type="pmid">10674711</pub-id></mixed-citation></ref><ref id="r22"><mixed-citation publication-type="journal" id="ref22"><string-name name-style="western"><surname>Hieronymus</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Emilsson</surname>, <given-names>J. F.</given-names></string-name>, <string-name name-style="western"><surname>Nilsson</surname>, <given-names>S.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Eriksson</surname>, <given-names>E.</given-names></string-name> (<year>2016</year>). <article-title>Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression</article-title>. <source>Molecular Psychiatry</source>, <volume>21</volume>(<issue>4</issue>), <fpage>523</fpage>&#8211;<lpage>530</lpage>. doi: <pub-id pub-id-type="doi">10.1038/mp.2015.53</pub-id><pub-id pub-id-type="pmid">25917369</pub-id><pub-id pub-id-type="pmcid">PMC4804177</pub-id></mixed-citation></ref><ref id="r23"><mixed-citation publication-type="journal" id="ref23"><string-name name-style="western"><surname>Iacobucci</surname>, <given-names>G.</given-names></string-name> (<year>2019</year>). <article-title>NHS prescribed record number of antidepressants last year</article-title>. <source>BMJ (Clinical Research Ed.)</source>, <volume>364</volume>, <fpage>l1508</fpage>. doi: <pub-id pub-id-type="doi">10.1136/BMJ.L1508</pub-id><pub-id pub-id-type="pmid">30926584</pub-id></mixed-citation></ref><ref id="r24"><mixed-citation publication-type="journal" id="ref24"><string-name name-style="western"><surname>Ionova</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Ashenhurst</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Zhan</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Nhan</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Kosinski</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Tamraz</surname>, <given-names>B.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>). <article-title>CYP2C19 allele frequencies in over 2.2 million direct-to-consumer genetics research participants and the potential implication for prescriptions in a large health system</article-title>. <source>Clinical and Translational Science</source>, <volume>13</volume>(<issue>6</issue>), <fpage>1298</fpage>&#8211;<lpage>1306</lpage>. doi: <pub-id pub-id-type="doi">10.1111/cts.12830</pub-id><pub-id pub-id-type="pmid">32506666</pub-id><pub-id pub-id-type="pmcid">PMC7719394</pub-id></mixed-citation></ref><ref id="r25"><mixed-citation publication-type="journal" id="ref25"><string-name name-style="western"><surname>Ising</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Lucae</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Binder</surname>, <given-names>E. B.</given-names></string-name>, <string-name name-style="western"><surname>Bettecken</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Uhr</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Ripke</surname>, <given-names>S.</given-names></string-name>, <etal>et al.</etal> (<year>2009</year>). <article-title>A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression</article-title>. <source>Archives of General Psychiatry</source>, <volume>66</volume>(<issue>9</issue>), <fpage>966</fpage>&#8211;<lpage>975</lpage>. doi: <pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2009.95</pub-id><pub-id pub-id-type="pmid">19736353</pub-id><pub-id pub-id-type="pmcid">PMC4465570</pub-id></mixed-citation></ref><ref id="r26"><mixed-citation publication-type="journal" id="ref26"><string-name name-style="western"><surname>Jakubovski</surname>, <given-names>E.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Bloch</surname>, <given-names>M. H.</given-names></string-name> (<year>2014</year>). <article-title>Prognostic subgroups for citalopram response in the STAR*D trial</article-title>. <source>The Journal of Clinical Psychiatry</source>, <volume>75</volume>(<issue>7</issue>), <fpage>738</fpage>&#8211;<lpage>747</lpage>. doi: <pub-id pub-id-type="doi">10.4088/JCP.13m08727</pub-id><pub-id pub-id-type="pmid">24912106</pub-id><pub-id pub-id-type="pmcid">PMC4471174</pub-id></mixed-citation></ref><ref id="r27"><mixed-citation publication-type="journal" id="ref27"><string-name name-style="western"><surname>Ji</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Biernacka</surname>, <given-names>J. M.</given-names></string-name>, <string-name name-style="western"><surname>Hebbring</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Chai</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Jenkins</surname>, <given-names>G. D.</given-names></string-name>, <string-name name-style="western"><surname>Batzler</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal> (<year>2013</year>). <article-title>Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: Genome-wide associations and functional genomics</article-title>. <source>The Pharmacogenomics Journal</source>, <volume>13</volume>(<issue>5</issue>), <fpage>456</fpage>&#8211;<lpage>463</lpage>. doi: <pub-id pub-id-type="doi">10.1038/tpj.2012.32</pub-id><pub-id pub-id-type="pmid">22907730</pub-id><pub-id pub-id-type="pmcid">PMC3941038</pub-id></mixed-citation></ref><ref id="r28"><mixed-citation publication-type="journal" id="ref28"><string-name name-style="western"><surname>Karrouri</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Hammani</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><surname>Benjelloun</surname>, <given-names>R.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Otheman</surname>, <given-names>Y.</given-names></string-name> (<year>2021</year>). <article-title>Major depressive disorder: Validated treatments and future challenges</article-title>. <source>World Journal of Clinical Cases</source>, <volume>9</volume>(<issue>31</issue>), <fpage>9350</fpage>&#8211;<lpage>9367</lpage>. doi: <pub-id pub-id-type="doi">10.12998/wjcc.v9.i31.9350</pub-id><pub-id pub-id-type="pmid">34877271</pub-id><pub-id pub-id-type="pmcid">PMC8610877</pub-id></mixed-citation></ref><ref id="r29"><mixed-citation publication-type="journal" id="ref29"><string-name name-style="western"><surname>Kessler</surname>, <given-names>R. C.</given-names></string-name>, <string-name name-style="western"><surname>van Loo</surname>, <given-names>H. M.</given-names></string-name>, <string-name name-style="western"><surname>Wardenaar</surname>, <given-names>K. J.</given-names></string-name>, <string-name name-style="western"><surname>Bossarte</surname>, <given-names>R. M.</given-names></string-name>, <string-name name-style="western"><surname>Brenner</surname>, <given-names>L. A.</given-names></string-name>, <string-name name-style="western"><surname>Ebert</surname>, <given-names>D. D.</given-names></string-name>, <etal>et al.</etal> (<year>2017</year>). <article-title>Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder</article-title>. <source>Epidemiology and Psychiatric Sciences</source>, <volume>26</volume>(<issue>1</issue>), <fpage>22</fpage>&#8211;<lpage>36</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S2045796016000020</pub-id><pub-id pub-id-type="pmid">26810628</pub-id><pub-id pub-id-type="pmcid">PMC5125904</pub-id></mixed-citation></ref><ref id="r30"><mixed-citation publication-type="journal" id="ref30"><string-name name-style="western"><surname>Khan</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Brodhead</surname>, <given-names>A. E.</given-names></string-name>, <string-name name-style="western"><surname>Schwartz</surname>, <given-names>K. A.</given-names></string-name>, <string-name name-style="western"><surname>Kolts</surname>, <given-names>R. L.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Brown</surname>, <given-names>W. A.</given-names></string-name> (<year>2005</year>). <article-title>Sex Differences in Antidepressant Response in Recent Antidepressant Clinical Trials</article-title>. <source>Journal of Clinical Psychopharmacology</source>, <volume>25</volume>(<issue>4</issue>). Retrieved from <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.lww.com/psychopharmacology/fulltext/2005/08000/sex_differences_in_antidepressant_response_in.5.aspx">https://journals.lww.com/psychopharmacology/fulltext/2005/08000/sex_differences_in_antidepressant_response_in.5.aspx</uri><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.jcp.0000168879.03169.ce</pub-id><pub-id pub-id-type="pmid">16012273</pub-id></mixed-citation></ref><ref id="r31"><mixed-citation publication-type="other" id="ref31"><string-name name-style="western"><surname>Koch</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>J&#252;rgenson</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Einarsson</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Harder</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Garc&#237;a-Mar&#237;n</surname>, <given-names>L. M.</given-names></string-name>, (<year>2024</year>). Genome-wide meta-analyses of non-response to antidepressants identify novel loci and potential drugs. <italic toggle="yes">MedRxiv.</italic> doi: <pub-id pub-id-type="doi">10.1101/2024.07.13.24310361</pub-id></mixed-citation></ref><ref id="r32"><mixed-citation publication-type="journal" id="ref32"><string-name name-style="western"><surname>Li</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Pain</surname>, <given-names>O.</given-names></string-name>, <string-name name-style="western"><surname>Chiara</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname>, <given-names>W. L. E.</given-names></string-name>, <string-name name-style="western"><surname>Lo</surname>, <given-names>C. W. H.</given-names></string-name>, <string-name name-style="western"><surname>Ripke</surname>, <given-names>S.</given-names></string-name>, <etal>et al.</etal> (<year>2024</year>). <article-title>Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: A meta-analysis</article-title>. <source>Translational Psychiatry</source>, <volume>14</volume>(<issue>1</issue>), <fpage>296</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41398-024-02981-1</pub-id><pub-id pub-id-type="pmid">39025838</pub-id><pub-id pub-id-type="pmcid">PMC11258238</pub-id></mixed-citation></ref><ref id="r33"><mixed-citation publication-type="other" id="ref33"><string-name name-style="western"><surname>Lo</surname>, <given-names>C. W. H.</given-names></string-name>, <string-name name-style="western"><surname>Gillett</surname>, <given-names>A. C.</given-names></string-name>, <string-name name-style="western"><surname>Iveson</surname>, <given-names>M. H.</given-names></string-name>, <string-name name-style="western"><surname>Kamp</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Fabbri</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname>, <given-names>W. L. E.</given-names></string-name>, <italic toggle="yes">Washington, D.C.</italic> (<year>2024</year>). Antidepressant switching as a proxy phenotype for drug non-response: Investigating clinical, demographic and genetic characteristics. <italic toggle="yes">MedRxiv</italic>, 2024.11.09.24316987. doi: <pub-id pub-id-type="doi">10.1101/2024.11.09.24316987</pub-id></mixed-citation></ref><ref id="r34"><mixed-citation publication-type="journal" id="ref34"><string-name name-style="western"><surname>McInnes</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Lavertu</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Sangkuhl</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Klein</surname>, <given-names>T. E.</given-names></string-name>, <string-name name-style="western"><surname>Whirl-Carrillo</surname>, <given-names>M.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Altman</surname>, <given-names>R. B.</given-names></string-name> (<year>2021</year>). <article-title>Pharmacogenetics at scale: An analysis of the UK Biobank</article-title>. <source>Clinical Pharmacology and Therapeutics</source>, <volume>109</volume>(<issue>6</issue>), <fpage>1528</fpage>&#8211;<lpage>1537</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cpt.2122</pub-id><pub-id pub-id-type="pmid">33237584</pub-id><pub-id pub-id-type="pmcid">PMC8144239</pub-id></mixed-citation></ref><ref id="r35"><mixed-citation publication-type="journal" id="ref35"><string-name name-style="western"><surname>Mills</surname>, <given-names>J. A.</given-names></string-name>, <string-name name-style="western"><surname>Suresh</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Mayes</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Croarkin</surname>, <given-names>P. E.</given-names></string-name>, <string-name name-style="western"><surname>Trivedi</surname>, <given-names>M. H.</given-names></string-name>, (<year>2022</year>). <article-title>Socioeconomic predictors of treatment outcomes among adults with major depressive disorder</article-title>. <source>Psychiatric Services (Washington, D.C.)</source>, <volume>73</volume>(<issue>9</issue>), <fpage>965</fpage>&#8211;<lpage>969</lpage>. doi: <pub-id pub-id-type="doi">10.1176/appi.ps.202100559</pub-id><pub-id pub-id-type="pmid">35354325</pub-id><pub-id pub-id-type="pmcid">PMC9629028</pub-id></mixed-citation></ref><ref id="r36"><mixed-citation publication-type="journal" id="ref36"><string-name name-style="western"><surname>Ni</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Revez</surname>, <given-names>J. A.</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname>, <given-names>T.</given-names></string-name>, (<year>2021</year>). <article-title>A comparison of ten polygenic score methods for psychiatric disorders applied across multiple cohorts</article-title>. <source>Biological Psychiatry</source>, <volume>90</volume>(<issue>9</issue>), <fpage>611</fpage>&#8211;<lpage>620</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biopsych.2021.04.018</pub-id><pub-id pub-id-type="pmid">34304866</pub-id><pub-id pub-id-type="pmcid">PMC8500913</pub-id></mixed-citation></ref><ref id="r37"><mixed-citation publication-type="other" id="ref37"><collab>NICE</collab> (<year>2009</year>). <source>Depression in adults: Recognition and management</source>.<pub-id pub-id-type="pmid">31990491</pub-id></mixed-citation></ref><ref id="r38"><mixed-citation publication-type="journal" id="ref38"><string-name name-style="western"><surname>Obach</surname>, <given-names>R. S.</given-names></string-name>, <string-name name-style="western"><surname>Cox</surname>, <given-names>L. M.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Tremaine</surname>, <given-names>L. M.</given-names></string-name> (<year>2005</year>). <article-title>Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: An in vitro study</article-title>. <source>Drug Metabolism and Disposition</source>, <volume>33</volume>(<issue>2</issue>), <fpage>262 LP</fpage>&#8211;<lpage>270</lpage>. doi: <pub-id pub-id-type="doi">10.1124/dmd.104.002428</pub-id><pub-id pub-id-type="pmid">15547048</pub-id></mixed-citation></ref><ref id="r39"><mixed-citation publication-type="journal" id="ref39"><string-name name-style="western"><surname>Otte</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Gold</surname>, <given-names>S. M.</given-names></string-name>, <string-name name-style="western"><surname>Penninx</surname>, <given-names>B. W.</given-names></string-name>, <string-name name-style="western"><surname>Pariante</surname>, <given-names>C. M.</given-names></string-name>, <string-name name-style="western"><surname>Etkin</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Fava</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal> (<year>2016</year>). <article-title>Major depressive disorder</article-title>. <source>Nature Reviews Disease Primers</source>, <volume>2</volume>(<issue>1</issue>), <fpage>1</fpage>&#8211;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrdp.2016.65</pub-id><pub-id pub-id-type="pmid">27629598</pub-id></mixed-citation></ref><ref id="r40"><mixed-citation publication-type="other" id="ref40"><string-name name-style="western"><surname>Pain</surname>, <given-names>O.</given-names></string-name>, <string-name name-style="western"><surname>Al-Chalabi</surname>, <given-names>A.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Lewis</surname>, <given-names>C.</given-names></string-name> (<year>2024</year>). <source>The GenoPred Pipeline: A Comprehensive and Scalable Pipeline for Polygenic Scoring</source>. doi: <pub-id pub-id-type="doi">10.1101/2024.06.12.24308843</pub-id><pub-id pub-id-type="pmcid">PMC11462442</pub-id><pub-id pub-id-type="pmid">39292536</pub-id></mixed-citation></ref><ref id="r41"><mixed-citation publication-type="journal" id="ref41"><string-name name-style="western"><surname>Pain</surname>, <given-names>O.</given-names></string-name>, <string-name name-style="western"><surname>Hodgson</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Trubetskoy</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Ripke</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Marshe</surname>, <given-names>V. S.</given-names></string-name>, <string-name name-style="western"><surname>Adams</surname>, <given-names>M. J.</given-names></string-name>, <etal>et al.</etal> (<year>2022</year>). <article-title>Identifying the common genetic basis of antidepressant response</article-title>. <source>Biological Psychiatry Global Open Science</source>, <volume>2</volume>(<issue>2</issue>), <fpage>115</fpage>&#8211;<lpage>126</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bpsgos.2021.07.008</pub-id><pub-id pub-id-type="pmid">35712048</pub-id><pub-id pub-id-type="pmcid">PMC9117153</pub-id></mixed-citation></ref><ref id="r42"><mixed-citation publication-type="journal" id="ref42"><string-name name-style="western"><surname>Pardi&#241;as</surname>, <given-names>A. F.</given-names></string-name>, <string-name name-style="western"><surname>Holmans</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Pocklington</surname>, <given-names>A. J.</given-names></string-name>, <string-name name-style="western"><surname>Escott-Price</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Ripke</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Carrera</surname>, <given-names>N.</given-names></string-name>, <etal>et al.</etal> (<year>2018</year>). <article-title>Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection</article-title>. <source>Nature Genetics</source>, <volume>50</volume>(<issue>3</issue>), <fpage>381</fpage>&#8211;<lpage>389</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41588-018-0059-2</pub-id><pub-id pub-id-type="pmid">29483656</pub-id><pub-id pub-id-type="pmcid">PMC5918692</pub-id></mixed-citation></ref><ref id="r43"><mixed-citation publication-type="journal" id="ref43"><string-name name-style="western"><surname>Perna</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Alciati</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Dacc&#242;</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Grassi</surname>, <given-names>M.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Caldirola</surname>, <given-names>D.</given-names></string-name> (<year>2020</year>). <article-title>Personalized psychiatry and depression: The role of sociodemographic and clinical variables</article-title>. <source>Psychiatry Investigation</source>, <volume>17</volume>(<issue>3</issue>), <fpage>193</fpage>&#8211;<lpage>206</lpage>. doi: <pub-id pub-id-type="doi">10.30773/pi.2019.0289</pub-id><pub-id pub-id-type="pmid">32160691</pub-id><pub-id pub-id-type="pmcid">PMC7113177</pub-id></mixed-citation></ref><ref id="r44"><mixed-citation publication-type="book" id="ref44"><collab>R Core Team</collab>. (<year>2021</year>). <source>R: A language and environment for statistical computing</source>. <publisher-loc>Vienna, Austria</publisher-loc>: <publisher-name>R Foundation for Statistical Computing</publisher-name>. Retrieved from <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.r-project.org/">https://www.r-project.org/</uri></mixed-citation></ref><ref id="r45"><mixed-citation publication-type="journal" id="ref45"><string-name name-style="western"><surname>Ramanuj</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Ferenchick</surname>, <given-names>E. K.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Pincus</surname>, <given-names>H. A.</given-names></string-name> (<year>2019</year>). <article-title>Depression in primary care: Part 2-management</article-title>. <source>BMJ (Clinical Research Ed.)</source>, <volume>365</volume>, <fpage>l835</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmj.l835</pub-id><pub-id pub-id-type="pmid">30962249</pub-id></mixed-citation></ref><ref id="r46"><mixed-citation publication-type="journal" id="ref46"><string-name name-style="western"><surname>Rayner</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Coleman</surname>, <given-names>J. R. I.</given-names></string-name>, <string-name name-style="western"><surname>Purves</surname>, <given-names>K. L.</given-names></string-name>, <string-name name-style="western"><surname>Carr</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Cheesman</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Davies</surname>, <given-names>M. R.</given-names></string-name>, (<year>2021</year>). <article-title>Sociodemographic factors associated with treatment-seeking and treatment receipt: Cross-sectional analysis of UK Biobank participants with lifetime generalised anxiety or major depressive disorder</article-title>. <source>BJPsych Open</source>, <volume>7</volume>(<issue>6</issue>), <fpage>e216</fpage>. doi: <pub-id pub-id-type="doi">10.1192/bjo.2021.1012</pub-id></mixed-citation></ref><ref id="r47"><mixed-citation publication-type="journal" id="ref47"><string-name name-style="western"><surname>Rush</surname>, <given-names>A. J.</given-names></string-name>, <string-name name-style="western"><surname>Fava</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Wisniewski</surname>, <given-names>S. R.</given-names></string-name>, <string-name name-style="western"><surname>Lavori</surname>, <given-names>P. W.</given-names></string-name>, <string-name name-style="western"><surname>Trivedi</surname>, <given-names>M. H.</given-names></string-name>, <string-name name-style="western"><surname>Sackeim</surname>, <given-names>H. A.</given-names></string-name>, <etal>et al.</etal> (<year>2004</year>). <article-title>Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design</article-title>. <source>Controlled Clinical Trials</source>, <volume>25</volume>(<issue>1</issue>), <fpage>119</fpage>&#8211;<lpage>142</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0197-2456(03)00112-0</pub-id><pub-id pub-id-type="pmid">15061154</pub-id></mixed-citation></ref><ref id="r48"><mixed-citation publication-type="journal" id="ref48"><string-name name-style="western"><surname>Rush</surname>, <given-names>A. J.</given-names></string-name>, <string-name name-style="western"><surname>Trivedi</surname>, <given-names>M. H.</given-names></string-name>, <string-name name-style="western"><surname>Stewart</surname>, <given-names>J. W.</given-names></string-name>, <string-name name-style="western"><surname>Nierenberg</surname>, <given-names>A. A.</given-names></string-name>, <string-name name-style="western"><surname>Fava</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Kurian</surname>, <given-names>B. T.</given-names></string-name>, <etal>et al.</etal> (<year>2011</year>). <article-title>Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study</article-title>. <source>American Journal of Psychiatry</source>, <volume>168</volume>(<issue>7</issue>), <fpage>689</fpage>&#8211;<lpage>701</lpage>. doi: <pub-id pub-id-type="doi">10.1176/appi.ajp.2011.10111645</pub-id><pub-id pub-id-type="pmid">21536692</pub-id></mixed-citation></ref><ref id="r49"><mixed-citation publication-type="journal" id="ref49"><string-name name-style="western"><surname>Rush</surname>, <given-names>A. J.</given-names></string-name>, <string-name name-style="western"><surname>Trivedi</surname>, <given-names>M. H.</given-names></string-name>, <string-name name-style="western"><surname>Wisniewski</surname>, <given-names>S. R.</given-names></string-name>, <string-name name-style="western"><surname>Nierenberg</surname>, <given-names>A. A.</given-names></string-name>, <string-name name-style="western"><surname>Stewart</surname>, <given-names>J. W.</given-names></string-name>, <string-name name-style="western"><surname>Warden</surname>, <given-names>D.</given-names></string-name>, <etal>et al.</etal> (<year>2006</year>). <article-title>Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report</article-title>. <source>The American Journal of Psychiatry</source>, <volume>163</volume>(<issue>11</issue>), <fpage>1905</fpage>&#8211;<lpage>1917</lpage>. doi: <pub-id pub-id-type="doi">10.1176/ajp.2006.163.11.1905</pub-id><pub-id pub-id-type="pmid">17074942</pub-id></mixed-citation></ref><ref id="r50"><mixed-citation publication-type="journal" id="ref50"><string-name name-style="western"><surname>Sangkuhl</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Whirl-Carrillo</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Whaley</surname>, <given-names>R. M.</given-names></string-name>, <string-name name-style="western"><surname>Woon</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Lavertu</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Altman</surname>, <given-names>R. B.</given-names></string-name>, <etal>et al.</etal> (<year>2020</year>). <article-title>Pharmacogenomics Clinical Annotation Tool (PharmCAT)</article-title>. <source>Clinical Pharmacology &amp; Therapeutics</source>, <volume>107</volume>(<issue>1</issue>), <fpage>203</fpage>&#8211;<lpage>210</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cpt.1568</pub-id><pub-id pub-id-type="pmid">31306493</pub-id><pub-id pub-id-type="pmcid">PMC6977333</pub-id></mixed-citation></ref><ref id="r51"><mixed-citation publication-type="journal" id="ref51"><string-name name-style="western"><surname>Saveanu</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Etkin</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Duchemin</surname>, <given-names>A.-M.</given-names></string-name>, <string-name name-style="western"><surname>Goldstein-Piekarski</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Gyurak</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Debattista</surname>, <given-names>C.</given-names></string-name>, <etal>et al.</etal> (<year>2015</year>). <article-title>The international Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment</article-title>. <source>Journal of Psychiatric Research</source>, <volume>61</volume>, <fpage>1</fpage>&#8211;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jpsychires.2014.12.018</pub-id><pub-id pub-id-type="pmid">25586212</pub-id></mixed-citation></ref><ref id="r52"><mixed-citation publication-type="journal" id="ref52"><string-name name-style="western"><surname>Serretti</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Gibiino</surname>, <given-names>S.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Drago</surname>, <given-names>A.</given-names></string-name> (<year>2011</year>). <article-title>Specificity profile of paroxetine in major depressive disorder: Meta-regression of double-blind, randomized clinical trials</article-title>. <source>Journal of Affective Disorders</source>, <volume>132</volume>(<issue>1&#8211;2</issue>), <fpage>14</fpage>&#8211;<lpage>25</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jad.2010.08.018</pub-id><pub-id pub-id-type="pmid">20863574</pub-id></mixed-citation></ref><ref id="r53"><mixed-citation publication-type="journal" id="ref53"><string-name name-style="western"><surname>Souery</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Serretti</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Calati</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Oswald</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Massat</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><surname>Konstantinidis</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal> (<year>2011</year>). <article-title>Switching antidepressant class does not improve response or remission in treatment-resistant depression</article-title>. <source>Journal of Clinical Psychopharmacology</source>, <volume>31</volume>(<issue>4</issue>), <fpage>512</fpage>&#8211;<lpage>516</lpage>. doi: <pub-id pub-id-type="doi">10.1097/JCP.0b013e3182228619</pub-id><pub-id pub-id-type="pmid">21694617</pub-id></mixed-citation></ref><ref id="r54"><mixed-citation publication-type="journal" id="ref54"><string-name name-style="western"><surname>Stahl</surname>, <given-names>E. A.</given-names></string-name>, <string-name name-style="western"><surname>Breen</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Forstner</surname>, <given-names>A. J.</given-names></string-name>, <string-name name-style="western"><surname>McQuillin</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Ripke</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Trubetskoy</surname>, <given-names>V.</given-names></string-name>, <etal>et al.</etal> (<year>2019</year>). <article-title>Genome-wide association study identifies 30 loci associated with bipolar disorder</article-title>. <source>Nature Genetics</source>, <volume>51</volume>(<issue>5</issue>), <fpage>793</fpage>&#8211;<lpage>803</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41588-019-0397-8</pub-id><pub-id pub-id-type="pmid">31043756</pub-id><pub-id pub-id-type="pmcid">PMC6956732</pub-id></mixed-citation></ref><ref id="r55"><mixed-citation publication-type="other" id="ref55"><string-name name-style="western"><surname>Sternat</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Mohammed</surname>, <given-names>T.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Furtado</surname>, <given-names>T.</given-names></string-name> (<year>2016</year>). <source>SSRI treatment response may predict undetected attention deficit hyperactivity disorder in depressed patients</source>. In <italic toggle="yes">Anxiety and Depression Association of America (ADAA) Conference 2016</italic>, Abstract S2&#8211;10.</mixed-citation></ref><ref id="r56"><mixed-citation publication-type="journal" id="ref56"><string-name name-style="western"><surname>Stone</surname>, <given-names>M. B.</given-names></string-name>, <string-name name-style="western"><surname>Yaseen</surname>, <given-names>Z. S.</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname>, <given-names>B. J.</given-names></string-name>, <string-name name-style="western"><surname>Richardville</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Kalaria</surname>, <given-names>S. N.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Kirsch</surname>, <given-names>I.</given-names></string-name> (<year>2022</year>). <article-title>Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: Individual participant data analysis</article-title>. <source>BMJ</source>, <volume>378</volume>. doi: <pub-id pub-id-type="doi">10.1136/bmj-2021-067606</pub-id><pub-id pub-id-type="pmcid">PMC9344377</pub-id><pub-id pub-id-type="pmid">35918097</pub-id></mixed-citation></ref><ref id="r57"><mixed-citation publication-type="journal" id="ref57"><string-name name-style="western"><surname>Strawn</surname>, <given-names>J. R.</given-names></string-name>, <string-name name-style="western"><surname>Mills</surname>, <given-names>J. A.</given-names></string-name>, <string-name name-style="western"><surname>Suresh</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Mayes</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Gentry</surname>, <given-names>M. T.</given-names></string-name>, <string-name name-style="western"><surname>Trivedi</surname>, <given-names>M.</given-names></string-name>, <etal>et al.</etal> (<year>2023</year>). <article-title>The impact of age on antidepressant response: A mega-analysis of individuals with major depressive disorder</article-title>. <source>Journal of Psychiatric Research</source>, <volume>159</volume>, <fpage>266</fpage>&#8211;<lpage>273</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jpsychires.2023.01.043</pub-id><pub-id pub-id-type="pmid">36774767</pub-id><pub-id pub-id-type="pmcid">PMC9993423</pub-id></mixed-citation></ref><ref id="r58"><mixed-citation publication-type="journal" id="ref58"><string-name name-style="western"><surname>Tansey</surname>, <given-names>K. E.</given-names></string-name>, <string-name name-style="western"><surname>Guipponi</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><surname>Domenici</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Malafosse</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal> (<year>2013</year>). <article-title>Contribution of common genetic variants to antidepressant response</article-title>. <source>Biological Psychiatry</source>, <volume>73</volume>(<issue>7</issue>), <fpage>679</fpage>&#8211;<lpage>682</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biopsych.2012.10.030</pub-id><pub-id pub-id-type="pmid">23237317</pub-id></mixed-citation></ref><ref id="r59"><mixed-citation publication-type="journal" id="ref59"><string-name name-style="western"><surname>Trivedi</surname>, <given-names>M. H.</given-names></string-name>, <string-name name-style="western"><surname>Rush</surname>, <given-names>A. J.</given-names></string-name>, <string-name name-style="western"><surname>Wisniewski</surname>, <given-names>S. R.</given-names></string-name>, <string-name name-style="western"><surname>Nierenberg</surname>, <given-names>A. A.</given-names></string-name>, <string-name name-style="western"><surname>Warden</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Ritz</surname>, <given-names>L.</given-names></string-name>, <etal>et al.</etal> (<year>2006</year>). <article-title>Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice</article-title>. <source>American Journal of Psychiatry</source>, <volume>163</volume>(<issue>1</issue>), <fpage>28</fpage>&#8211;<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.1176/appi.ajp.163.1.28</pub-id><pub-id pub-id-type="pmid">16390886</pub-id></mixed-citation></ref><ref id="r60"><mixed-citation publication-type="journal" id="ref60"><string-name name-style="western"><surname>Uher</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Huezo-Diaz</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Perroud</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Rietschel</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Mors</surname>, <given-names>O.</given-names></string-name>, <etal>et al.</etal> (<year>2009</year>). <article-title>Genetic predictors of response to antidepressants in the GENDEP project</article-title>. <source>The Pharmacogenomics Journal</source>, <volume>9</volume>(<issue>4</issue>), <fpage>225</fpage>&#8211;<lpage>233</lpage>. doi: <pub-id pub-id-type="doi">10.1038/tpj.2009.12</pub-id><pub-id pub-id-type="pmid">19365399</pub-id></mixed-citation></ref><ref id="r61"><mixed-citation publication-type="journal" id="ref61"><string-name name-style="western"><surname>Uher</surname>, <given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Perlis</surname>, <given-names>R. H.</given-names></string-name>, <string-name name-style="western"><surname>Henigsberg</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Zobel</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Rietschel</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Mors</surname>, <given-names>O.</given-names></string-name>, <etal>et al.</etal> (<year>2012</year>). <article-title>Depression symptom dimensions as predictors of antidepressant treatment outcome: Replicable evidence for interest-activity symptoms</article-title>. <source>Psychological Medicine</source>, <volume>42</volume>(<issue>5</issue>), <fpage>967</fpage>&#8211;<lpage>980</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S0033291711001905</pub-id><pub-id pub-id-type="pmid">21929846</pub-id><pub-id pub-id-type="pmcid">PMC3787526</pub-id></mixed-citation></ref><ref id="r62"><mixed-citation publication-type="journal" id="ref62"><string-name name-style="western"><surname>Uher</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Maier</surname>, <given-names>W.</given-names></string-name>, <string-name name-style="western"><surname>Hauser</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Maru&#353;i&#269;</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Schmael</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Mors</surname>, <given-names>O.</given-names></string-name>, <etal>et al.</etal> (<year>2009</year>). <article-title>Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression</article-title>. <source>British Journal of Psychiatry</source>, <volume>194</volume>(<issue>3</issue>), <fpage>252</fpage>&#8211;<lpage>259</lpage>. doi: <pub-id pub-id-type="doi">10.1192/bjp.bp.108.057554</pub-id><pub-id pub-id-type="pmid">19252156</pub-id></mixed-citation></ref><ref id="r63"><mixed-citation publication-type="journal" id="ref63"><string-name name-style="western"><surname>Valerio</surname>, <given-names>M. P.</given-names></string-name>, <string-name name-style="western"><surname>Szmulewicz</surname>, <given-names>A. G.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Martino</surname>, <given-names>D. J.</given-names></string-name> (<year>2018</year>). <article-title>A quantitative review on outcome-to-antidepressants in melancholic unipolar depression</article-title>. <source>Psychiatry Research</source>, <volume>265</volume>, <fpage>100</fpage>&#8211;<lpage>110</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.psychres.2018.03.088</pub-id><pub-id pub-id-type="pmid">29702301</pub-id></mixed-citation></ref><ref id="r64"><mixed-citation publication-type="other" id="ref64"><collab>Wellcome Trust</collab>. (<year>n.d.</year>). <article-title>Embedding lived experience expertise in mental health research. Retrieved September 16, 2024</article-title>, from <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://wellcome.org/grant-funding/guidance/embedding-lived-experience-expertise-mental-health-research">https://wellcome.org/grant-funding/guidance/embedding-lived-experience-expertise-mental-health-research</uri></mixed-citation></ref><ref id="r65"><mixed-citation publication-type="journal" id="ref65"><string-name name-style="western"><surname>Wong</surname>, <given-names>W. L. E.</given-names></string-name>, <string-name name-style="western"><surname>Fabbri</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Laplace</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Li</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>van Westrhenen</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname>, <given-names>C. M.</given-names></string-name>, <etal>et al.</etal> (<year>2023</year>). <article-title>The effects of CYP2C19 genotype on proxies of SSRI antidepressant response in the UK Biobank</article-title>. <source>Pharmaceuticals (Basel, Switzerland)</source>, <volume>16</volume>(<issue>9</issue>). doi: <pub-id pub-id-type="doi">10.3390/ph16091277</pub-id><pub-id pub-id-type="pmcid">PMC10535191</pub-id><pub-id pub-id-type="pmid">37765085</pub-id></mixed-citation></ref><ref id="r66"><mixed-citation publication-type="book" id="ref66"><collab>World Health Organization</collab>. (<year>1993</year>). <source>Composite International Diagnostic Interview &#8211; Version 1.1</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>WHO</publisher-name>. doi: <pub-id pub-id-type="doi">10.1163/_q3_SIM_00374</pub-id></mixed-citation></ref><ref id="r67"><mixed-citation publication-type="journal" id="ref67"><string-name name-style="western"><surname>Wray</surname>, <given-names>N. R.</given-names></string-name>, <string-name name-style="western"><surname>Ripke</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Mattheisen</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Trzaskowski</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Byrne</surname>, <given-names>E. M.</given-names></string-name>, <string-name name-style="western"><surname>Abdellaoui</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal> (<year>2018</year>). <article-title>Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression</article-title>. <source>Nature Genetics</source>, <volume>50</volume>(<issue>5</issue>), <fpage>668</fpage>&#8211;<lpage>681</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41588-018-0090-3</pub-id><pub-id pub-id-type="pmid">29700475</pub-id><pub-id pub-id-type="pmcid">PMC5934326</pub-id></mixed-citation></ref><ref id="r68"><mixed-citation publication-type="journal" id="ref68"><string-name name-style="western"><surname>Yuce-Artun</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Baskak</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Ozel-Kizil</surname>, <given-names>E. T.</given-names></string-name>, <string-name name-style="western"><surname>Ozdemir</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Uckun</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><surname>Devrimci-Ozguven</surname>, <given-names>H.</given-names></string-name>, <etal>et al.</etal> (<year>2016</year>). <article-title>Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients</article-title>. <source>International Journal of Clinical Pharmacy</source>, <volume>38</volume>(<issue>2</issue>), <fpage>388</fpage>&#8211;<lpage>394</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11096-016-0259-8</pub-id><pub-id pub-id-type="pmid">26830411</pub-id></mixed-citation></ref><ref id="r69"><mixed-citation publication-type="journal" id="ref69"><string-name name-style="western"><surname>Zimmerman</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>McGlinchey</surname>, <given-names>J. B.</given-names></string-name>, <string-name name-style="western"><surname>Posternak</surname>, <given-names>M. A.</given-names></string-name>, <string-name name-style="western"><surname>Friedman</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Attiullah</surname>, <given-names>N.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Boerescu</surname>, <given-names>D.</given-names></string-name> (<year>2006</year>). <article-title>How should remission from depression be defined? The depressed patient&#8217;s perspective</article-title>. <source>The American Journal of Psychiatry</source>, <volume>163</volume>(<issue>1</issue>), <fpage>148</fpage>&#8211;<lpage>150</lpage>. doi: <pub-id pub-id-type="doi">10.1176/appi.ajp.163.1.148</pub-id><pub-id pub-id-type="pmid">16390903</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>